<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TREGA BIOSCIENCES, INC.
- --------------------------------------------------------------------------------
(NAME OF ISSUER)
COMMON STOCK, $.001 PAR VALUE
- --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
894699107
- --------------------------------------------------------------------------------
(CUSIP NUMBER)
GEORGE M. GRASS, PH.D.
C/O NAVICYTE INC.
351 EAST GLENDALE AVENUE
SPARKS, NV 89341
(702) 353-3700
- --------------------------------------------------------------------------------
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON
AUTHORIZED TO RECEIVE NOTICES AND COMMUNICATIONS)
NOVEMBER 23, 1998
- --------------------------------------------------------------------------------
(DATE OF EVENT WHICH REQUIRES FILING
OF THIS STATEMENT)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]
NOTE: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom copies
are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on following pages)
(Page 1 of 6 Pages)
<PAGE> 2
CUSIP NO. 894699107 13D Page 2 of 6 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
GEORGE M. GRASS, Ph.D.
###-##-####
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
00
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
USA
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
1,428,231
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON 1,428,231
WITH ----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,428,231
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
9.0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- --------------------------------------------------------------------------------
-2-
<PAGE> 3
ITEM 1. SECURITY AND ISSUER
(a) Title of Security:
Trega Biosciences, Inc. Common Stock, $.001 par value per share
(the "Common Stock")
(b) Name of Issuer:
Trega Biosciences, Inc., a Delaware corporation ("Trega").
(c) Address of Issuer's Principal Executive Office:
The principal executive office of Trega is located at 9880 Campus
Point Drive, San Diego, California, 92121.
ITEM 2. IDENTITY AND BACKGROUND
(a) This statement is filed by George M. Grass, Ph.D., an individual
("Dr. Grass").
(b) The business address of Dr. Grass is c/o NaviCyte, Inc., 851 East
Glendale Avenue, Sparks, Nevada, 89431.
(c) Dr. Grass' principal occupation or employment is President of
NaviCyte, Inc., 851 East Glendale Avenue, Sparks, Nevada, 89431.
(d) During the last five years, there have been no criminal proceedings
against Dr. Grass.
(e) During the last five years, Dr. Grass has not been a party to any
civil proceeding of a judicial or administrative body of competent jurisdiction
resulting in a judgment, decree or final order enjoining future violations of,
or prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.
(f) Dr. Grass is a citizen of the United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
The securities were acquired upon the consummation of the Merger (as
defined in Item 4 below).
ITEM 4. PURPOSE OF THE TRANSACTION
(a) Not applicable, except that, as an employee of a wholly owned
subsidiary of Trega (NaviCyte), Dr. Grass expects to receive options to accrue
additional shares of Trega's Common Stock. Arrangements between NaviCyte and Dr.
Grass presently call for the grant of an option to acquire an additional 150,000
shares of Trega's Common Stock (the "Option").
-3-
<PAGE> 4
(b) Pursuant to the terms of an Agreement and Plan of Reorganization,
dated November 12, 1998 (the "Merger Agreement") among Trega, TBNC Acquisition
Corporation, a Delaware corporation and a wholly-owned subsidiary of Trega
("Acquisition Corporation"), NaviCyte, Inc., a Delaware corporation
("NaviCyte"), George M. Grass, Ph.D. and Patrick J. Sinko, Ph.D, Acquisition
Corporation was merged with and into NaviCyte (the "Merger"), with NaviCyte
being the surviving corporation. Effective as of November 23, 1998, Trega
acquired all of the outstanding shares of NaviCyte capital stock. As a result of
the Merger, the following has taken place: (i) holders of NaviCyte capital stock
prior to the Merger have received, in the aggregate: (a) $210,000 in cash and
(b) 1,428,231 shares of Trega Common Stock (all of which have been issued to Dr.
Grass); and (ii) holders of options to acquire NaviCyte capital stock prior to
the Merger ("NaviCyte Option Holders") have received, in the aggregate, options
to acquire 1,071,756 shares of Trega Common Stock (which amount is not subject
to vesting). An amount representing 25% of the total shares of Trega Common
Stock issued to Dr. Grass and an amount representing 25% of the shares of Trega
Common Stock issuable to each NaviCyte Option Holder upon exercise of their
respective options shall be "Escrow Shares" (as defined in the Merger
Agreement).
The foregoing description of the transactions involving Trega and
NaviCyte and the various agreements entered into in connection therewith is
qualified in its entirety by reference to the Merger Agreement, a copy of which
is filed as an exhibit to this Schedule 13D and incorporated herein by this
reference.
(c) Not applicable.
(d) Not applicable.
(e) None, other than a change in the number of outstanding shares of
Trega Common Stock as contemplated by the Merger Agreement (and, potentially,
the Option).
(f) Upon consummation of the Merger, NaviCyte became a wholly owned
subsidiary of Trega.
(g) Not applicable.
(h) Not applicable.
(i) Not applicable.
(j) Not applicable.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) - (b) Dr. Grass is the sole beneficial owner of, has sole power to
vote and has sole power to dispose of 1,428,231 shares of Trega Common Stock.
Such shares constitute approximately 9.0% of the issued and outstanding shares
of Trega Common Stock as of November 23, 1998. The business address of Dr. Grass
is c/o NaviCyte, Inc., 851 East Glendale Avenue, Sparks, Nevada, 89431.
Dr. Grass' principal occupation or employment is President of NaviCyte, Inc.,
851 East Glendale Avenue, Sparks, Nevada, 89431.
-4-
<PAGE> 5
During the last five years, there have been no criminal proceedings against Dr.
Grass.
During the last five years, Dr. Grass has not been a party to any civil
proceeding of a judicial or administrative body of competent jurisdiction
resulting in a judgment, decree or final order enjoining future violations of,
or prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.
Dr. Grass is a citizen of the United States.
(c) Dr. Grass has not effected any transaction in Trega Common Stock
during the past 60 days, except as disclosed herein.
(d) Not applicable.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER
Upon the effectiveness of the Merger, Dr. Grass remained as President of
NaviCyte. In connection with the Merger, Dr. Grass has signed an employment
agreement with NaviCyte.
Dr. Grass, as well as full-time NaviCyte employees, are (to the extent
not treated by continuation of NaviCyte benefit plans) eligible to participate
in Trega employee benefit plans, including Trega's stock option plan.
Other than as described in the foregoing paragraph and in Item 4 above,
there are no contracts, arrangements, understandings or relationships (legal or
otherwise) among the persons named in Item 2 and between such persons and any
person with respect to any securities of Trega, including but not limited to
transfer or voting of any securities, finder's fees, joint ventures, loan or
option arrangements, puts or calls, guarantees of profits, division of profits
or loss, or the giving or withholding of proxies.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<S> <C>
99.1 Agreement and Plan of Merger and Reorganization dated as of November 12,
1998, by and among Trega Biosciences, Inc., a Delaware corporation, TBNC
Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary
of Trega, NaviCyte, Inc., a Delaware corporation, George M. Grass, Ph.D. and
Patrick J. Sinko, Ph.D.
99.2 Employment Agreement dated November 10, 1998 between NaviCyte, Inc. and
George M. Grass, Ph.D.
</TABLE>
-5-
<PAGE> 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: December 1, 1998
/s/ GEORGE M. GRASS
----------------------------------------
George M. Grass, Ph.D.
-6-
<PAGE> 7
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
------- -----------
<S> <C>
99.1 Agreement and Plan of Merger and Reorganization dated
as of November 12, 1998, by and among Trega
Biosciences, Inc., a Delaware corporation, TBNC
Acquisition Corporation, a Delaware corporation and a
wholly-owned subsidiary of Trega, NaviCyte, Inc., a
Delaware corporation, George M. Grass, Ph.D. and
Patrick J. Sinko, Ph.D.
99.2 Employment Agreement dated November 10, 1998
between NaviCyte, Inc. and George M. Grass, Ph.D.
</TABLE>
<PAGE> 1
EXHIBIT 99.1
AGREEMENT AND PLAN OF REORGANIZATION
THIS AGREEMENT AND PLAN OF REORGANIZATION (this "AGREEMENT") is made and
entered into as of November 12, 1998 by and among TREGA BIOSCIENCES, INC., a
Delaware corporation ("TREGA"), TBNC ACQUISITION CORPORATION, a Delaware
corporation and the wholly-owned subsidiary of Trega ("ACQUISITION
CORPORATION"), NAVICYTE, INC., a Delaware corporation ("NAVICYTE"), GEORGE M.
GRASS, Ph.D., an individual stockholder, director and officer of NaviCyte, and
PATRICK J. SINKO, Ph.D., an individual securityholder, director and officer of
NaviCyte (the foregoing individuals, owning all of the outstanding shares of
NaviCyte and a majority of the outstanding shares on a fully diluted basis,
being herein referred to as the "NAVICYTE MAJORITY STOCKHOLDERS"). NaviCyte and
Acquisition Corporation are herein sometimes referred to as the "CONSTITUENT
CORPORATIONS," NaviCyte, Acquisition Corporation and Trega are herein sometimes
referred to as the "CORPORATE PARTIES" and the Corporate Parties and the
NaviCyte Majority Stockholders are herein sometimes referred to as the
"PARTIES." This Agreement is entered into with reference to the following facts:
A. The Parties intend that, subject to the terms and conditions
hereinafter set forth, (i) Acquisition Corporation will be merged with and into
NaviCyte (the "MERGER") and (ii) all outstanding shares of the Common Stock, par
value $0.0001 per share, of NaviCyte ("NAVICYTE COMMON STOCK"), as well as all
options to acquire NaviCyte Common Stock, will be converted into the right to
receive, in the aggregate, up to (x) 2,500,000 shares of the Common Stock,
$0.001 par value, of Trega ("TREGA COMMON STOCK") and (y) $210,000.00 in cash,
all in accordance with the provisions and subject to the terms and conditions
set forth in this Agreement.
B. The Parties desire to enter into this Agreement for the purpose of
setting forth certain representations, warranties and covenants made by each to
the other as an inducement to the Merger and the conditions precedent to the
consummation of the Merger.
NOW, THEREFORE, in consideration of the premises and of the mutual
provisions, agreements and covenants herein contained, the Parties agree as
follows:
ARTICLE 1
THE MERGER
1.1 The Merger. Subject to the terms and conditions of this Agreement,
at the Effective Time (as defined in Section 1.3 below) Acquisition Corporation
shall be merged with and into NaviCyte in the Merger and the separate corporate
existence of Acquisition Corporation shall thereupon cease.
1.2 Closing. The closing of the Merger (the "CLOSING") shall take place
(i) at the offices of Pillsbury Madison & Sutro LLP, 101 West Broadway Street,
San Diego, CA at
<PAGE> 2
9:00 A.M. on the first business day on which the last to be fulfilled or waived
of the conditions set forth in Article 5 hereof shall be fulfilled or waived in
accordance with this Agreement or (ii) at such other place and time and/or on
such other date as Trega and NaviCyte may agree in writing (in any event, the
"CLOSING DATE"). Except as otherwise provided herein, the Closing may be
conducted by means of exchange of documents via telecopy, with original
documents to be exchanged by overnight mail.
1.3 Effective Time. As soon as practicable following the Closing, and
provided that this Agreement shall not have been terminated or abandoned
pursuant to Article 7 hereof, the Corporate Parties shall cause a Certificate of
Merger in substantially the form attached hereto as EXHIBIT A (the "DELAWARE
CERTIFICATE OF MERGER") to be executed and filed with the Secretary of State of
Delaware as provided in Section 251 of the Delaware General Corporation Law (the
"DGCL"). The Merger shall become effective at the time and on the date on which
the Delaware Certificate of Merger has been duly filed with the Secretary of
State of Delaware, and such time is hereinafter referred to as the "EFFECTIVE
TIME."
1.4 Effects of the Merger. NaviCyte shall be the surviving corporation
in the Merger (sometimes hereinafter referred to as the "SURVIVING CORPORATION")
and shall continue to be governed by the laws of the State of Delaware, and the
separate corporate existence of NaviCyte with all its rights, privileges,
immunities, powers and franchises shall continue unaffected by the Merger. The
Merger shall have the effects specified in the DGCL. At the Effective Time:
(a) The Certificate of Incorporation of NaviCyte, in the form
attached hereto as EXHIBIT B (the "NAVICYTE CHARTER"), shall continue as the
Certificate of Incorporation of the Surviving Corporation.
(b) The bylaws of Acquisition Corporation, as in effect
immediately prior to the Effective Time, shall become the bylaws of the
Surviving Corporation without change or amendment until altered, amended or
repealed as provided for in such bylaws or by law.
(c) The directors and officers of Surviving Corporation shall be
as follows:
<TABLE>
<CAPTION>
Directors and Chairman:
-----------------------
<S> <C>
Lawrence D. Muscheck, Ph.D Chairman
George M. Grass, Ph.D.
Debra K. Liebert
Officers:
George M. Grass, Ph.D. President and Chief Executive Officer
Debra K. Liebert Treasurer, Chief Financial Officer and Secretary
</TABLE>
1.5 Effect on Securities. As of the Effective Time, by virtue of the
Merger and without any action on the part of the Corporate Parties or any
stockholder thereof, the securities
-2-
<PAGE> 3
of the Constituent Corporations outstanding at the Effective Time shall be
converted or treated as follows:
(a) Capital Stock of Acquisition Corporation. All issued and
outstanding shares of capital stock of Acquisition Corporation shall continue to
be issued and shall be converted into 100 shares of Common Stock, $0.001 par
value, of the Surviving Corporation. Each stock certificate formerly evidencing
ownership of any shares of capital stock of Acquisition Corporation shall
continue following the Effective Time to evidence ownership of shares of capital
stock of the Surviving Corporation.
(b) Cancellation of NaviCyte-Owned and Trega-Owned Stock. All
shares of NaviCyte Common Stock, if any, that are owned directly or indirectly
by NaviCyte or Trega shall be canceled, and no stock of Trega or other
consideration shall be delivered in exchange therefor.
(c) Conversion of NaviCyte Common Stock.
(i) Per Share Merger Consideration. Other than shares to
be canceled pursuant to Section 1.5(b) and fractional shares as provided
in Section 1.5(e), each share of NaviCyte Common Stock issued and
outstanding immediately prior to the Effective Time, and all rights
existing with respect thereto, shall cease to be outstanding and shall
be converted, without any action on the part of the holder thereof, into
the right, as of the Effective Time, to receive a bundle of
consideration comprised of (X) and (Y) (collectively, "PER SHARE MERGER
CONSIDERATION") where:
(X) = the quotient of $210,000.00 (the "CASH") divided by
the number of shares of NaviCyte Common Stock
outstanding as of immediately prior to the Effective
Time; and
(Y) = the quotient of 2,500,000 shares of Trega Common Stock
(the "TOTAL SHARES") divided by the number of shares of
NaviCyte Common Stock outstanding as of immediately
prior to the Effective Time on a fully-diluted basis
(i.e., assuming that all NaviCyte Options (defined
below) were fully vested, all NaviCyte Options were
fully exercised and any other contingent rights to
acquire shares of NaviCyte Common Stock were also fully
exercised)(herein referred to as the "NUMBER OF FULLY
DILUTED NAVICYTE SHARES OUTSTANDING");[1] provided,
however, that one-fourth (1/4) of the Total Shares to
be issued as of the Effective Time (e.g., 625,000 shares
of Trega Common Stock if all NaviCyte Options (as
defined below) are exercised prior to the
- ---------------
1 For example, if the capitalization of NaviCyte at the Effective Time is
identical to the capitalization of NaviCyte as represented in this
Agreement, the Number of Fully Diluted NaviCyte Shares Outstanding would
be a total of 2,100,500 shares determined as follows: (i) 1,200,000
shares of NaviCyte Common Stock issued and outstanding; plus (ii)
900,500 shares issuable upon the exercise in full of all outstanding
NaviCyte Options.
-3-
<PAGE> 4
Effective Time) will be placed into the Escrow Account
(as defined below) and be subject to the terms thereof
as provided in Section 1.5(c)(iii) below. The Total
Shares to be issued as of the Effective Time which are
not placed into the Escrow Account (e.g., 1,875,000
shares of Trega Common Stock if all NaviCyte Options are
exercised prior to the Effective Time) are herein
referred to as the "CURRENT SHARES."[2]
An example of calculations with respect to Per Share Merger
Consideration, based on certain assumptions regarding the Number of
Fully Diluted NaviCyte Shares Outstanding, is set forth on SCHEDULE 0
attached hereto.
(ii) Distribution of Current Shares and Cash. Promptly
after the Effective Time, Trega shall make available in exchange for
certificates representing shares of NaviCyte Common Stock outstanding
immediately prior to the Effective Time in accordance with this Article
1 (including Section 1.8 below) both (x) certificates representing the
Current Shares and (y) funds representing, in the aggregate, the Cash.
In addition to any restrictions applicable under federal and state
securities laws (e.g., as a result of the "restricted" status of the
Current Shares under the 1933 Act (defined below)), the Current Shares
shall be nontransferable for a period of one year following the Closing
Date.
(iii) Escrow Shares. An amount of Trega Common Stock
representing one-fourth (1/4) of the Total Shares to be issued as of the
Effective Time (i.e., up to 625,000 shares of Trega Common Stock - the
"ESCROW SHARES") shall be delivered by Trega, promptly following the
Effective Time, into the "ESCROW ACCOUNT" as defined in, and pursuant to
the terms of, the Escrow Agreement attached hereto as EXHIBIT C (the
"ESCROW AGREEMENT"). The Escrow Shares shall (A) be held in the Escrow
Account for the benefit of the Entitled Holders (as defined below) on a
pro rata basis (as set forth in Section 1.5(c)(iv) below) and shall be
released therefrom only when and as provided by the Escrow Agreement,
this Agreement and SCHEDULE 1 attached hereto ("SCHEDULE 1"), (B) be
subject to the conditions, requirements and agreements set forth in this
Agreement (including, without limitation, Trega's Lien (as defined in
Section 6.1(a) below) and the Offset Right (as defined in Section 6.1(a)
below) as set forth in the provisions of Article 6 below and SCHEDULE 1)
and (C) not be assignable or transferable unless and until released
pursuant to the terms of the Escrow Agreement, this Agreement and
SCHEDULE 1. During such time as any Escrow Shares remain in the Escrow
Account, each Entitled Holder shall be entitled to exercise any and all
voting and other consensual rights pertaining to the Escrow Shares then
being held for such Entitled Holder's benefit. Entitled Holders also
shall be entitled to receive and retain any and all cash dividends paid
in respect of such Escrow Shares; provided, however,
- --------
2 In the event that all NaviCyte Options are not exercised prior to the
Effective Time, then upon the exercise of any Trega Substitute Option
(as defined in Section 1.5(d) below) following the Effective Time,
one-fourth (1/4) of the shares of Trega Common Stock thereupon issuable
shall be "Escrow Shares" as provided in SCHEDULE 2 attached hereto.
-4-
<PAGE> 5
that any and all of the following shall be issued and/or delivered by
Trega or any third party into the Escrow Account to be held pursuant to
the terms of this Agreement (including, without limitation, subject to
the Offset Right and Trega's Lien) and the Escrow Agreement, and shall
constitute "Escrow Shares" for all purposes hereunder: (x) dividends
paid or payable (other than in cash) and instruments and other property
received, receivable or otherwise distributed or distributable in
respect of or in exchange for any Escrow Shares; (y) any and all cash
paid, payable or otherwise distributed in respect of any Escrow Shares
(whether in redemption of or exchange for any Escrow Shares or
otherwise), except for any cash dividends as provided above; and (z) any
and all securities or property which may be paid in respect of any
Escrow Shares by reason of any consolidation, merger, exchange of
shares, conveyance of assets, liquidation or similar event affecting
Trega or the securityholders of Trega (an "EVENT"). Furthermore, in the
event that Trega, at any time or from time to time after the Effective
Time, shall effect a subdivision of the outstanding shares of Trega
Common Stock into a greater number of shares (by stock split,
reclassification or otherwise than by payment of a dividend in Trega
Common Stock or any right to acquire Trega Common Stock), or in the
event that the outstanding shares of Trega Common Stock shall be
combined or consolidated, by reclassification or otherwise, into a
lesser number of shares of Trega Common Stock, then the Escrow Shares
shall be treated in the same manner as such outstanding shares of Trega
Common Stock.
Notwithstanding the foregoing or any other provision of this Agreement
(including, without limitation, SCHEDULE 1), in the event that the
employment of George M. Grass, Ph.D. is terminated by Trega or NaviCyte,
or any successor entity, following any Event and without Cause (as
defined below), then the date of any such termination shall be deemed to
be the Second Anniversary for purposes of SCHEDULE 1 attached hereto.
"CAUSE" shall mean a decision to terminate the employment of Dr. Grass
for any (1) material failure to perform his job, (2) breach of any
employment agreement, (3) violation of applicable policy(ies), (4)
insubordination, (5) failure to devote full time and energy to the
business of Trega, NaviCyte or any successor entity, (6) failure to
protect the trade secrets of any such entity or (7) other conduct which,
in the good faith judgment of the board of directors of any such entity,
is inconsistent with the performance by Dr. Grass of his job at a
reasonable level of competence.
(iv) Distribution of Escrow Shares. Escrow Shares shall be
distributed to persons entitled thereto as and when provided in SCHEDULE
1. For each former stockholder of NaviCyte to whom Current Shares were
available for exchange at the Effective Time (each being an "ENTITLED
HOLDER"), promptly following such time as any amount of Escrow Shares (a
"TRANCHE") may become distributable pursuant to SCHEDULE 1 (i.e., the
related contingencies, including timing, with respect to such Tranche
are met or observed pursuant to SCHEDULE 1), Trega shall cause to be
distributed to such Entitled Holder a number of Escrow Shares which
shall represent such Entitled Holder's proportionate amount of such
Tranche (together with any cash in lieu of fractional shares as provided
in Section 1.5(e) below); provided, however, that notwithstanding any
other provision of this Agreement to the contrary (including, without
limitation, SCHEDULE 1), if, when a distribution of Escrow Shares would
-5-
<PAGE> 6
otherwise occur under the provisions of this Agreement, Trega shall have
made, in accordance with the provisions of Section 6.2 below, a good
faith claim to exercise its Offset Right (as defined in Section 6.1(a)
below) which claim has not been perfected or has otherwise been objected
to (as provided in Section 6.3 below), an amount of such Escrow Shares
having a value equal to the Damages (as defined in Section 6.1(a) below)
at issue (pursuant to Section 6.2 below) shall be withheld from
distribution until such time as either (x) the claim has been perfected,
in which case the Offset Right shall apply against such shares, or (y)
resolution of the objection has been ultimately determined (e.g.,
without the possibility of further appeal), in which case the
consequences of such determination shall ensue.
Each Entitled Holder's proportionate amount of a Tranche shall be the
product of (A) multiplied by (B) where:
(A) Is the number of shares of Trega Common Stock comprising
such Tranche; and
(B) Is the quotient of (x) the number of issued and
outstanding shares of NaviCyte Common Stock held by such
Entitled Holder immediately prior to the Effective Time
divided by (y) the Number of Fully Diluted NaviCyte Shares
Outstanding.
With respect to shares of NaviCyte Common Stock issued and outstanding
immediately prior to the Effective Time, Trega shall be entitled to
treat those holders properly surrendering Certificates to Trega or
Trega's transfer agent (as Trega may determine) as the Entitled Holders.
(d) [RESERVED].
(e) Fractional Shares. No fractional shares of Trega Common Stock
shall be issued (whether in connection with the distribution of Current Shares
or a Tranche, upon the exercise of any Trega Substitute Option (as defined
below), or otherwise), but in lieu thereof each person who would otherwise be
entitled to receive a fraction of a share of Trega Common Stock (after
aggregating all fractional shares of Trega Common Stock which may then be
received by such person) shall receive from Trega an amount of cash (rounded up
to the nearest whole cent) equal to the product of (i) the fraction of a share
of Trega Common Stock to which such holder would otherwise be entitled
multiplied by (ii) the closing price of Trega Common Stock quoted on the Nasdaq
National Market on the trading day immediately preceding the Closing Date.
(f) Legends. Certificates evidencing Current Shares shall bear
the following two legends (or their substantial equivalents) and certificates
evidencing Escrow Shares shall bear the first of the following two legends (or
its substantial equivalent):
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE
-6-
<PAGE> 7
"SECURITIES ACT"), AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR
OTHERWISE DISPOSED OF UNLESS SO REGISTERED AND QUALIFIED OR UNLESS
EXEMPTIONS ARE AVAILABLE, TO THE SATISFACTION OF THE ISSUER, OR UNLESS
SOLD PURSUANT TO RULE 144 OF THE SECURITIES ACT.
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD,
TRANSFERRED OR OTHERWISE DISPOSED OF UNTIL [_____________ __, 1999] [ONE
YEAR FOLLOWING THE CLOSING DATE].
1.6 NaviCyte Stock Options. With respect to each option to purchase
NaviCyte Common Stock outstanding as of immediately prior to the Effective Time
and which is not being exercised prior to the Effective Time (together, the
"NAVICYTE OPTIONS"):
(a) NaviCyte shall (intending to affect adversely those holders of
NaviCyte Options who do not agree to accept a Trega Substitute Option
(as defined below) in lieu of all rights under their NaviCyte Options)
terminate all rights of any holder of any NaviCyte Option as of the
Effective Time without any acceleration of vesting or any other
acceleration or modification of rights with respect thereto; and
(b) Trega shall assume the related pre-Effective Time obligations of
NaviCyte with respect to any such NaviCyte Option (as well as related
obligations, if any, under the 1997 NaviCyte Stock Plan - a copy of
which is attached as EXHIBIT 2-A to SCHEDULE 2 attached hereto), subject
to the modification of the terms of any such NaviCyte Option (and the
rights of any holder thereof) to comply with the terms set forth on
SCHEDULE 2 attached hereto (including, without limitation, that (i) any
such NaviCyte Option, from and after the Effective Time, shall be
exercisable solely for shares of Trega Common Stock under the terms
provided for on SCHEDULE 2 attached hereto and (ii) no further vesting
shall occur under any NaviCyte Option or Trega Substitute Option).
Collectively, any option-related obligations assumed by Trega pursuant
to this paragraph (b) are herein referred to as the "TREGA SUBSTITUTE
OPTIONS".
1.7 Dissenting NaviCyte Shares. Without limiting the provisions of
Sections 5.2(c) and 5.2(k) below, shares of NaviCyte Common Stock which are not
voted in favor of the Merger and with respect to which a demand for payment and
appraisal in respect of the Merger shall have been properly made in accordance
with the DGCL ("DISSENTING NAVICYTE SHARES") shall not be converted into present
and contingent rights to receive Per Share Merger Consideration as set forth in
Section 1.5 above unless and until the holder of such shares withdraws its
demand or becomes ineligible for such payment and appraisal. If a holder of
Dissenting NaviCyte Shares shall withdraw its demand for such payment and
appraisal or shall become ineligible for such payment and appraisal, then as of
the Effective Time or the occurrence of such event of withdrawal or
ineligibility, whichever last occurs, such holder's Dissenting NaviCyte Shares
shall cease to be Dissenting NaviCyte Shares and shall be converted into the
right to receive, and shall be exchangeable for, the present and contingent
rights to receive Per Share Merger Consideration into which such Dissenting
NaviCyte Shares
-7-
<PAGE> 8
would have been converted pursuant to Section 1.5 above (subject, without
limitation, to the delivery of one-fourth (1/4) of the shares of Trega Common
Stock represented thereby into the Escrow Account as provided in Section
1.5(c)(iii) above).
1.8 Exchange of Certificates for Current Shares.
(a) Letter of Transmittal. As soon as practicable after the
Effective Time, Trega shall mail to each holder of record of a certificate or
certificates which immediately prior to the Effective Time represented
outstanding shares of NaviCyte Common Stock (the "CERTIFICATES") and who has not
surrendered their Certificates at the Closing, a letter of transmittal and
instructions for use in effecting the surrender of Certificates in exchange for
Current Shares and Cash. Upon surrender of a Certificate for cancellation to
Trega or Trega's transfer agent (as Trega may determine), the holder of such
Certificate shall be entitled to receive in exchange therefor an amount of
Current Shares, a portion of the Cash and a payment in lieu of any fractional
Current Share, all as determined pursuant to Section 1.5 above. Each Certificate
so surrendered shall thereupon be canceled.
(b) Transfers of Shares. In the event of a transfer of ownership
of NaviCyte Common Stock which is not registered in the transfer records of
NaviCyte, any stock certificates representing Current Shares, the applicable
portion of the Cash and any cash in lieu of any fractional Current Share may be
delivered to a transferee if the Certificate representing the right to receive
such Merger consideration is presented to Trega and accompanied by all documents
required or advisable to evidence and effect such transfer (including evidence
regarding compliance with applicable securities laws and that any applicable
taxes have been paid or withheld).
(c) Lost Certificates. Trega shall follow the same procedure with
respect to lost, stolen or mutilated Certificates as it follows with respect to
lost, stolen or mutilated certificates representing shares of Trega Common
Stock.
(d) Status of Unexchanged Shares. Unless and until a Certificate
shall be surrendered as provided in this Section 1.8, or procedures respecting
lost, stolen or mutilated Certificates are followed, the holder of the
Certificate shall not be entitled to receive (i) any Current Shares, (ii) any
Cash, (iii) any Escrow Shares or (iv) any cash for any fractional shares. Any
dividends paid or other distributions made to holders of record of Trega Common
Stock after the Effective Time shall, insofar as any Current Shares or Escrow
Shares issuable in exchange for unexchanged certificates are concerned, be paid
to and retained by Trega and paid over to such holder when such Certificate is
surrendered or such procedures are followed in accordance with this Section 1.8.
1.9 No Further Ownership Rights in NaviCyte Securities. All Trega Common
Stock, Cash and rights to acquire Trega Common Stock delivered upon the
surrender for exchange of, or deemed to be issued in replacement of, NaviCyte
Common Stock and NaviCyte Options (collectively, the "NAVICYTE SECURITIES") in
accordance with the terms hereof shall be deemed to have been delivered in full
satisfaction of all rights pertaining to such NaviCyte Securities. From and
after the Effective Time, there shall be no further registration of transfers on
the
-8-
<PAGE> 9
transfer books of the Surviving Corporation of the NaviCyte Securities which
were outstanding immediately prior to the Effective Time. If, after the
Effective Time, Certificates are presented to the Surviving Corporation for any
reason, they shall be canceled and exchanged only as provided in this Article 1.
1.10 Accounting/Tax Treatment.
(a) The Corporate Parties intend that the purchase method of
accounting will be used by Trega to account for the Merger.
(b) Tax Treatment. The Corporate Parties intend that the Merger
will be a reorganization within the meaning of Section 368(a) of the Internal
Revenue Code of 1986, as amended (the "CODE").
1.11 Additional Actions. If, at any time after the Effective Time, the
Surviving Corporation shall consider or be advised that any further deeds, bills
of sale, assignments or assurances in law or any other actions or things are
necessary or desirable (a) to vest, perfect or confirm, of record or otherwise,
in the Surviving Corporation its rights, title or interest in, to or under any
of the rights, property or assets of Acquisition Corporation as a result of, or
in connection with, the Merger or (b) otherwise to carry out the purposes of
this Agreement, Acquisition Corporation and its proper officers and directors
shall be deemed to have granted to the Surviving Corporation an irrevocable
power of attorney to execute and deliver all such proper deeds, bills of sale,
assignments and assurances in law and to take and do all such other actions as
may be necessary or desirable to vest, perfect or confirm any and all right,
title and interest in, to and under such rights, properties or assets in the
Surviving Corporation and otherwise to carry out the purposes of this Agreement;
and the proper officers and directors of the Surviving Corporation are fully
authorized in the name of Acquisition Corporation or otherwise to take any and
all such actions.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES OF NAVICYTE
AND NAVICYTE MAJORITY STOCKHOLDERS
Except as otherwise set forth in SCHEDULE 3 (the "NAVICYTE DISCLOSURE
SCHEDULE") delivered to Trega prior to the execution of this Agreement and
attached hereto (it being agreed that for any item set forth in the NaviCyte
Disclosure Schedule having relevance to more than one of the following sections
of this Article 2, disclosure in any one section shall constitute disclosure for
purposes of all applicable sections of the NaviCyte Disclosure Schedule),
NaviCyte and each of the NaviCyte Majority Stockholders, jointly and severally,
represents, warrants and covenants to Trega and Acquisition Corporation as
follows:
2.1 Organization. NaviCyte is a corporation (a) duly organized, validly
existing and in good standing under the laws of the State of Delaware and (b)
duly qualified and in good standing to do business as a foreign corporation in
the State of Nevada. NaviCyte is not
-9-
<PAGE> 10
required to be qualified to do business in any other jurisdiction. NaviCyte has
all requisite power and authority to own, lease and operate its properties and
to carry on its business as it is now being conducted. NaviCyte has heretofore
delivered to Trega true, correct and complete copies of the NaviCyte Charter and
NaviCyte's Bylaws (the "NAVICYTE BYLAWS") and all amendments thereto through and
including the Closing Date, and true, correct and complete copies of the minutes
of all meetings and other corporate actions of the directors, committees of the
directors and of the stockholders of NaviCyte since inception.
2.2 Capital Structure. The authorized capital stock of NaviCyte consists
of 10,000,000 shares of NaviCyte Common Stock and 3,000,000 shares of preferred
stock ("NAVICYTE PREFERRED STOCK"). Immediately prior to the Effective Time, (a)
1,200,000 shares of NaviCyte Common Stock will be issued and outstanding, (b)
900,500 shares of NaviCyte Common Stock will be reserved for issuance upon
exercise of the NaviCyte Options, and (c) no shares of NaviCyte Preferred Stock
will be issued and outstanding. A true, correct and complete list of holders of
NaviCyte Common Stock and NaviCyte Options, showing the number of shares and
options held by each such securityholder, is attached hereto as SCHEDULE 2.2.
All of the outstanding shares of NaviCyte Common Stock as well as the NaviCyte
Options have been issued or granted in compliance with applicable federal and
state securities laws. All of the outstanding shares of NaviCyte Common Stock
are, and any shares of NaviCyte Common Stock issuable upon exercise of any
NaviCyte Options when issued pursuant to such exercise will be, duly authorized,
validly issued, fully paid and nonassessable and not subject to preemptive
rights created by statute, the NaviCyte Charter, the NaviCyte Bylaws, the DGCL
or any agreement to which NaviCyte is a party or is bound.
2.3 Obligations With Respect to Capital Stock. NaviCyte has provided or
shall provide any required notices of the Merger or the transactions
contemplated hereby to (or obtain required consents for the Merger or the
transactions contemplated hereby from) the holders of all NaviCyte Securities.
Except as set forth in Section 2.2 above, (a) there are no equity securities of
any class of NaviCyte, or any security or obligation exchangeable into or
exercisable for such equity securities, issued, reserved for issuance or
outstanding and (b) there are not any options, warrants, calls, rights,
commitments or agreements of any character (i) to which NaviCyte is a party or
by which NaviCyte is bound obligating NaviCyte to issue, deliver or sell, or
cause to be issued, delivered or sold, additional shares of capital stock of
NaviCyte or obligating NaviCyte to grant, extend or enter into any such option,
warrant, call, right, commitment or agreement, or (ii) which could obligate
Trega to issue or deliver any Per Share Merger Consideration, any portion of the
Per Share Merger Consideration, other securities or cash. There are no voting
trusts, proxies or other agreements or understandings with respect to the voting
of shares of capital stock of NaviCyte or with respect to the purchase by any
person or entity, or the repurchase by NaviCyte, of any capital stock or other
securities of NaviCyte.
2.4 Equity Investments. NaviCyte does not own and has not subscribed or
otherwise agreed to purchase any equity interest, directly or indirectly, in any
corporation, partnership, joint venture, firm or other entity.
-10-
<PAGE> 11
2.5 Authority. NaviCyte has all requisite corporate power and authority
to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement, and the consummation of
the transactions contemplated hereby, have been duly authorized by all necessary
corporate action on the part of NaviCyte. This Agreement and related agreements
have been duly executed and delivered by NaviCyte, and such agreements
constitute valid and binding obligations of NaviCyte enforceable in accordance
with their terms, subject to (i) the effect of applicable bankruptcy,
insolvency, reorganization, moratorium or other similar federal or state laws
affecting the rights of creditors and (ii) the effect or availability of rules
of law governing specific performance, injunctive relief or other equitable
remedies (regardless of whether any such remedy is considered in a proceeding at
law or in equity). With the exception of a requirement for consent with respect
to certain lease agreements identified on SCHEDULE 2.5 attached hereto, the
execution and delivery of this Agreement does not, and the consummation of the
transactions contemplated hereby will not, conflict with, or result in any
violation of or default (with or without notice or lapse of time, or both)
under, or give rise to a right of termination, cancellation or acceleration of
any obligation or to loss of a material benefit under (a) any provision of the
NaviCyte Charter or the NaviCyte Bylaws, (b) any agreement or contract or any
instrument, permit, franchise, license, judgment or order applicable to NaviCyte
or its properties or assets or, (c) to the Best Knowledge (as defined in Section
8.10 below) of NaviCyte or the NaviCyte Majority Stockholders, any local, state,
federal or foreign statute, law, ordinance, regulation or rule applicable to
NaviCyte or its properties or assets. There are no consents, waivers or
approvals ("CONSENTS") of third parties applicable to NaviCyte or its operations
or business that are required to be obtained by NaviCyte or the NaviCyte
Majority Stockholders in connection with the execution and delivery of this
Agreement by such parties and the performance of their respective obligations
hereunder. No Consent, order or authorization of, or registration, declaration
or filing with, any court, administrative agency or commission or other
governmental authority or instrumentality (a "GOVERNMENTAL ENTITY") is required
by or with respect to NaviCyte or the NaviCyte Majority Stockholders in
connection with the execution and delivery of this Agreement by such parties and
the consummation of the transactions contemplated hereby, except for (a) the
filing of the Delaware Certificate of Merger with the Delaware Secretary of
State and (b) the filing of a Form D with the Securities and Exchange Commission
(the "SEC") (with reference to Section 4.9 below).
2.6 Financial Statements. Attached hereto as SCHEDULE 2.6 is (a)
NaviCyte's unaudited balance sheet as of June 30, 1998 and the related
statements of operations, changes in stockholders' equity and cash flows for the
nine (9) month period ended June 30, 1998 and (b) NaviCyte's unaudited balance
sheet as of September 30, 1998 and the related statements of operations, changes
in stockholders' equity and cash flows for the twelve (12) month period then
ended. The unaudited balance sheet at June 30, 1998 is hereinafter referred to
as the "NAVICYTE BALANCE SHEET," and all such financial statements are
hereinafter referred to collectively as the "NAVICYTE FINANCIAL STATEMENTS." The
NaviCyte Financial Statements have been prepared on a consistent basis during
the periods involved, are in accordance with NaviCyte's books and records, and
fairly present the financial position of NaviCyte and the results of its
operations as of the dates and for the periods indicated thereon. At the date of
the NaviCyte Balance Sheet (the "NAVICYTE BALANCE SHEET DATE") and as of the
Closing Date, NaviCyte had and has no liabilities or obligations, secured or
unsecured (whether accrued, abso-
-11-
<PAGE> 12
lute, contingent or otherwise - collectively, "LIABILITIES") not reflected on
the NaviCyte Balance Sheet except for Liabilities (x) as may have arisen in the
ordinary course of business prior to the date of the NaviCyte Balance Sheet and
which, under generally accepted accounting principles ("GAAP"), would not have
been required to be reflected on the NaviCyte Balance Sheet and (y) incurred in
the ordinary course of business since the date of the NaviCyte Balance Sheet
which are usual and normal in amount, but in any event not greater than
$50,000.00 in the aggregate (inclusive of clauses (x) and (y)).
2.7 Business Changes. Since the NaviCyte Balance Sheet Date (except as
otherwise expressly noted below with respect to a different "base date"), except
as otherwise contemplated by this Agreement or any other agreement between Trega
and NaviCyte or as otherwise set forth on SCHEDULE 2.7 attached hereto, NaviCyte
has conducted its business only in the ordinary and usual course and, without
limiting the generality of the foregoing:
(a) There have been no changes in the condition (financial or
otherwise), business, net worth, assets, properties, employees, operations or
Liabilities of NaviCyte (with a "base date" for measuring Liabilities, for
purposes of this clause (a), of September 30, 1998) which, in the aggregate,
have had or may be reasonably expected to have a material adverse effect on the
condition, business, net worth, assets, properties or operations of NaviCyte.
(b) NaviCyte has not issued, nor authorized for issuance, nor
entered into any commitment to issue, any equity security, bond, note or other
security of NaviCyte, except for shares of NaviCyte Common Stock issuable upon
the exercise of the outstanding NaviCyte Options as referenced on SCHEDULE 2.2
attached hereto.
(c) NaviCyte has not incurred additional debt for borrowed money,
nor incurred any Liability (with a "base date" for measuring Liabilities, for
purposes of this clause (c), of September 30, 1998).
(d) NaviCyte has not paid any Liability, nor discharged, settled
or satisfied any claim, lien or encumbrance, except for current Liabilities in
the ordinary and usual course of business and in any event not in excess of
$10,000.00 for any single occurrence or $50,000.00 in the aggregate.
(e) NaviCyte has not authorized, declared or made any dividend,
payment or other distribution on or with respect to any capital stock of
NaviCyte.
(f) NaviCyte has not purchased, redeemed or otherwise acquired or
committed itself to acquire, directly or indirectly, any capital stock of
NaviCyte.
(g) NaviCyte has not mortgaged, pledged, or otherwise,
voluntarily or involuntarily, encumbered or granted a lien or security interest
in any of its assets or properties, except for liens for current taxes which are
not yet delinquent.
(h) NaviCyte has not disposed of, or agreed to dispose of, by
sale, lease, license or otherwise, any asset or property, tangible or intangible
(except for the sale of
-12-
<PAGE> 13
inventory in the ordinary course of business or for assets or properties which
are immaterial, either alone or in the aggregate).
(i) NaviCyte has not (i) purchased or agreed to purchase or
otherwise acquire any securities of any corporation, partnership, joint venture,
firm or other entity or (ii) made any expenditure or commitment for the
purchase, license, acquisition, construction or improvement of a capital asset.
(j) NaviCyte has not entered into any transaction or contract, or
made any commitment to do the same, where more than $10,000.00 in value for any
single such transaction or contract is at issue, or where more than $50,000.00
in aggregate value for all such transactions and contracts is at issue.
(k) NaviCyte has not sold, assigned, transferred or conveyed, or
committed itself to sell, assign, transfer or convey, any Proprietary Rights (as
defined below).
(l) NaviCyte has not adopted or amended any bonus, incentive,
profit-sharing, stock option, stock purchase, pension, retirement,
deferred-compensation, severance, life insurance, medical or other benefit plan,
agreement, trust, fund or arrangement for the benefit of employees of any kind
whatsoever, nor entered into or amended any agreement relating to employment,
services as an independent contractor or consultant, or severance or termination
pay, nor agreed to do any of the foregoing.
(m) NaviCyte has not effected or agreed to effect any change in
its directors, officers, employees, consultants or advisors, and no officer,
employee, consultant or advisor of NaviCyte has indicated that he or she intends
to terminate his or her employment or relationship with NaviCyte.
(n) NaviCyte has not effected or committed itself to effect any
amendment or modification of the NaviCyte Charter or the NaviCyte Bylaws.
(o) To the Best Knowledge of NaviCyte or the NaviCyte Majority
Stockholders, no statute has been enacted nor has any rule or regulation been
adopted by any state where laws apply to the business of NaviCyte or any federal
or foreign agency or authority which may reasonably be expected to have a
material and adverse effect on the condition (financial or otherwise), business,
net worth, assets, prospects, properties, employees, operations or Liabilities
of NaviCyte which has not yet been reflected in the operating results of
NaviCyte.
2.8 Properties.
(a) NaviCyte owns no real property. The NaviCyte Balance Sheet
reflects all of the real and personal property used by NaviCyte in its business
or otherwise held by NaviCyte. Except as reflected in the notes to the NaviCyte
Balance Sheet, NaviCyte has good and marketable title to all assets and
properties listed on the NaviCyte Balance Sheet or thereafter acquired, free and
clear of any imperfections of title, lien, claim, encumbrance, restriction,
charge or equity of any nature whatsoever, except for the lien of current taxes
not
-13-
<PAGE> 14
yet delinquent. All of the fixed assets and properties reflected on the NaviCyte
Balance Sheet or thereafter acquired are in satisfactory condition and repair
(normal wear and tear excepted) for the requirements of the business as
presently conducted by NaviCyte.
(b) NaviCyte is, and at all times has been, in material
compliance with all local, state and federal statutes, orders, rules, ordinances
and regulations relating to pollution or protection of the environment,
including, without limitation, laws relating to exposures, emissions,
discharges, releases or threatened releases of Hazardous Substances (as defined
below) into or on land, ambient air, surface water, groundwater, personal
property or structures (including the protection, cleanup, removal, remediation
or damage thereof), or otherwise related to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport, discharge or
handling of Hazardous Substances. "HAZARDOUS SUBSTANCES" shall mean any
pollutant, contaminant, material, substance or waste regulated, restricted or
prohibited by any law, regulation or ordinance or designated by any governmental
agency to be hazardous, toxic, radioactive, biohazardous or otherwise a danger
to health or the environment.
(c) Except as set forth on SCHEDULE 2.8 attached hereto, (i)
NaviCyte has not used any Hazardous Substances in its operations and (ii) there
are no Hazardous Substances currently on any premises leased or occupied by
NaviCyte, nor have there ever been at any time during NaviCyte's occupancy, nor,
to the Actual Knowledge (as defined in Section 8.10 below) of NaviCyte or the
NaviCyte Majority Stockholders, have there ever been at any other time (whether
before or after NaviCyte's occupancy). No Hazardous Substances have ever been
disposed of on or about such premises by NaviCyte nor, to the Actual Knowledge
of NaviCyte or the NaviCyte Majority Stockholders, by any third party; and
NaviCyte has not disposed of any materials at any site being remediated or, to
the Actual Knowledge of NaviCyte or the NaviCyte Majority Stockholders,
investigated for contamination or possible contamination of the environment.
(d) There have been no judicial or administrative proceedings or
other investigations and there are no judicial or administrative proceedings or
other investigations pending or, to the Actual Knowledge of NaviCyte or the
NaviCyte Majority Stockholders, threatened alleging violation by NaviCyte of any
local, state or federal laws respecting land use, pollution or protection of the
environment including, without limitation, laws regulating the use, storage,
transportation or disposal of Hazardous Substances. NaviCyte has not received
any notice of any investigation, claim or proceeding against NaviCyte by any
individual or governmental entity relating to Hazardous Substances. Without
limiting the other provisions of this Section 2.8, to the Actual Knowledge of
NaviCyte or the NaviCyte Majority Stockholders, there exists no fact or
circumstance which could involve NaviCyte in any environmental litigation,
proceeding, investigation or claim or impose any environmental liability upon
NaviCyte.
(e) SCHEDULE 2.8 attached hereto includes a complete list of all
real property leased or occupied at any time by NaviCyte. All such property
leased or occupied by NaviCyte is or was held or occupied under valid and
enforceable leases or licenses and neither real property leased or occupied by
NaviCyte (to the Actual Knowledge of NaviCyte or the NaviCyte Majority
Stockholders) nor the operations of NaviCyte thereon violate any applicable
-14-
<PAGE> 15
building code, zoning requirement or classification, or pollution control
ordinance or statute relating to the property or to such operations, and such
non-violation is not dependent, in any instance, on so-called non-conforming use
exemptions.
(f) SCHEDULE 2.8 attached hereto includes a true, correct and
complete list of all permits, consents and approvals which NaviCyte is required
to have under local, state and federal laws respecting land use, pollution or
protection of the environment for the construction, maintenance or operation of
its facilities and the conduct or operation of its business. NaviCyte has
obtained each and every one of such permits, consents and approvals and is, and
at all times has been, in full compliance with each and every one of the terms
and conditions thereof. Further, all of the listed permits, consents and
approvals are in full force and effect, none have been modified, and there is no
proceeding pending or, to the Actual Knowledge of NaviCyte or the NaviCyte
Majority Stockholders, threatened which may result in the reversal, rescission,
termination, modification or suspension of any such permit, consent or approval.
(g) NaviCyte has kept all records and made all filings required
to be made by NaviCyte under or pursuant to all applicable local, state and
federal laws relating to land use, pollution and protection of the environment
with respect to all exposures, emissions, discharges and releases into the
environment and the proper use, storage, transportation and disposal of all
Hazardous Substances.
2.9 Personal Property. A true, correct and complete list of all personal
property assets having a fair market value in excess of $1,000.00 and all
computer software used in the conduct of NaviCyte's business (collectively, the
"SCHEDULED ASSETS") is attached hereto as SCHEDULE 2.9. NaviCyte has good and
marketable title to (or, as expressly disclosed on SCHEDULE 2.9, together with a
summary of the lease terms, a valid leasehold interest in) the Scheduled Assets
free and clear of any lien, claim or Liability. The Scheduled Assets are in good
condition and repair in all respects (normal wear and tear excepted) and are
suitable for the conduct of NaviCyte's business.
2.10 Taxes. NaviCyte has duly filed with the appropriate United States,
state, local and foreign governmental agencies all tax returns and reports
required to be filed, which returns are accurate and complete, and has paid or
accrued in full all taxes, duties, charges, withholding obligations and other
governmental liabilities as well as any interest, penalties, assessments or
deficiencies, if any, due to, or claimed to be due by, any Governmental Entity
(all such items are collectively referred to herein as "TAXES"). The NaviCyte
Balance Sheet fully accrues or reserves for all current and deferred Taxes.
NaviCyte is not a party to any pending action or proceeding, nor, to the Actual
Knowledge of NaviCyte or the NaviCyte Majority Stockholders, is any such action
or proceeding threatened by any Governmental Entity for the assessment or
collection of Taxes. Since the NaviCyte Balance Sheet Date, no liability for
Taxes has been incurred other than in the ordinary course of business. There are
no liens for Taxes except for liens for Taxes not yet delinquent. NaviCyte is
not a party to any Tax sharing, Tax allocation, Tax indemnity or statute of
limitations extension or waiver agreement and has never been included on any
consolidated, combined or unitary return with any entity.
-15-
<PAGE> 16
2.11 Compensation/Change in Control. A true, correct and complete list
of all directors, officers, employees or consultants of NaviCyte as of the date
hereof, specifying their names and job designations, their dates of hire, the
total amount paid or payable as wages, salaries or other forms of direct
compensation, and the basis of such compensation, whether fixed or commission or
a combination thereof, is attached hereto as SCHEDULE 2.11. There are no
provisions, contracts, agreements, terms or arrangements relating to any amounts
or benefits payable to any person or entity (whether currently payable or
payable in the future) relating to a change in control of NaviCyte (including,
without limitation, a change in control effected by the Merger).
2.12 Increases in Compensation. Except as set forth in SCHEDULE 2.12,
since the NaviCyte Balance Sheet Date, NaviCyte has not paid or committed itself
to pay to or for the benefit of any of its directors, officers, employees,
consultants, advisors or stockholders any compensation of any kind other than
wages, salaries and benefits at times and rates in effect on the NaviCyte
Balance Sheet Date, nor has NaviCyte effected or agreed to effect any amendment
or supplement to any employee profit sharing, stock option, stock purchase,
pension, bonus, incentive, retirement, medical reimbursement, life insurance,
deferred compensation or any other employee benefit plan or arrangement.
2.13 Compliance with Law.
(a) All material licenses, franchises, permits, clearances,
consents, certificates and other evidences of authority of NaviCyte which are
necessary to the conduct of NaviCyte's operations or business ("PERMITS") are in
full force and effect and NaviCyte is not in violation of any Permit in any
respect. The business of NaviCyte has been conducted in compliance with all
applicable laws, regulations, orders and other requirements of governmental
authorities, including, without limiting the generality of the foregoing, all
laws, regulations and orders relating to employment practices and procedures,
the health and safety of employees and export controls.
(b) There have been no judicial or administrative proceedings or
other investigations and there are no judicial or administrative proceedings or
other investigations pending or, to the Actual Knowledge of NaviCyte or the
NaviCyte Majority Stockholders, threatened alleging violation by NaviCyte of any
local, state, federal or foreign laws, regulations and orders respecting the
business of NaviCyte including, without limitation, laws, regulations and orders
promulgated under or by the Clinical Laboratory Improvement Act, the Food and
Drug Administration Act and any foreign, federal, state or local agencies
regulating clinical or research laboratories; and NaviCyte has not received any
notice of any investigation, claim or proceeding against NaviCyte by any such
governmental entity and, to the Best Knowledge of NaviCyte or the NaviCyte
Majority Stockholders, no fact or circumstance exists which could involve
NaviCyte in any such litigation, proceeding, investigation or claim or impose
any such liability upon NaviCyte.
2.14 Litigation. There is no claim, dispute, action, proceeding, notice,
order, suit, appeal or investigation, at law or in equity, pending against
NaviCyte, or involving any of its assets or properties, before any court,
agency, authority, arbitration panel or other tribunal, and,
-16-
<PAGE> 17
to the Actual Knowledge of NaviCyte or the NaviCyte Majority Stockholders, none
have been threatened. To the Best Knowledge of NaviCyte or the NaviCyte Majority
Stockholders, no facts exist which, if known to stockholders, customers,
governmental authorities or other persons, would result in any such claim,
dispute, action, proceeding, suit or appeal or investigation. NaviCyte is not
subject to any order, writ, injunction or decree of any court, agency,
authority, arbitration panel or other tribunal, nor is it in default with
respect to any notice, order, writ, injunction or decree.
2.15 Products and Services. All products manufactured or services
provided by NaviCyte heretofore and prior to the Effective Time have complied
and shall continue to comply in all respects with all warranties, express or
implied, applicable thereto. NaviCyte has not in any respect misrepresented its
products or services or employed misleading or deceptive advertising, packaging
or labeling in connection with the sale of its products or services.
2.16 Contracts.
(a) A complete list of each executory contract and agreement in
the following categories to which NaviCyte is a party, or by which it or its
assets or properties are bound in any respect, is attached hereto as SCHEDULE
2.16 (copies of which have been provided to Trega):
(i) agreements for the purchase, sale, lease or other
disposition of equipment, goods, materials, research and development, supplies,
studies or capital assets, or for the performance of services, in any case
involving more than $10,000.00 (combining, for this purpose, any series of
agreements with the same party or its affiliated entities);
(ii) contracts or agreements for the joint performance of
work or services, and all other joint venture agreements;
(iii) management or employment contracts, consulting
contracts, collective bargaining contracts, termination and severance
agreements;
(iv) notes, mortgages, deeds of trust, loan agreements,
security agreement, guarantees, debentures, indentures, credit agreements and
other evidences of indebtedness;
(v) pension, retirement, profit-sharing, deferred
compensation, bonus, incentive, life insurance, hospitalization or other
employee benefit plans or arrangements (including, without limitation, any
contracts or agreements with trustees, insurance companies or others relating to
any such employee benefit plan or arrangement);
(vi) stock option, stock purchase, warrant, repurchase or
other contracts or agreements relating to any capital stock of NaviCyte;
(vii) contracts or agreements with agents, brokers,
consignees, sale representatives or distributors;
-17-
<PAGE> 18
(viii) contracts or agreements with any director, officer,
employee, consultant or stockholder;
(ix) powers of attorney or similar authorizations granted
by NaviCyte to third parties;
(x) licenses, sublicenses, royalty agreements and other
contracts or agreements to which NaviCyte is a party, or to which the business
or any properties or assets of NaviCyte are otherwise subject (including,
without limitation, those arrangements relating to Proprietary Rights (as
defined below)); and
(xi) to the extent not listed elsewhere in this Agreement,
all other contracts material to the business of NaviCyte as presently conducted
and as proposed to be conducted.
(b) Neither NaviCyte nor any of its officers, directors,
consultants, agents or representatives has entered into any contract or
agreement containing covenants limiting the right of NaviCyte or its officers or
directors, or, to the Best Knowledge of NaviCyte or the NaviCyte Majority
Stockholders, its consultants, agents or representatives to compete in any
business or with any person.
As used in this Agreement, the terms "CONTRACT" and "AGREEMENT" include every
contract, agreement, commitment, understanding and promise.
2.17 No Default.
(a) Each of NaviCyte's contracts, agreements or other instruments
(including, without limitation, those referred to in SCHEDULE 2.16 attached
hereto) is a legal, binding and enforceable obligation by or against NaviCyte,
subject to the effect of applicable bankruptcy, insolvency, reorganization,
moratorium or other similar federal or state laws affecting the rights of
creditors and the effect or availability of rules of law governing specific
performance, injunctive relief or other equitable remedies (regardless of
whether any such remedy is considered in a proceeding at law or in equity). To
the Actual Knowledge of NaviCyte or the NaviCyte Majority Stockholders, no party
with whom NaviCyte has an agreement or contract is in default thereunder or has
breached any terms or provisions thereof.
(b) NaviCyte has performed, or is now performing, the obligations
of, and NaviCyte is not in default (or would by the lapse of time and/or the
giving of notice be in default) in respect of, any contract, agreement or
commitment binding upon it or any of its assets or properties. No third party
has raised any claim, dispute or controversy with respect to any of the
executory contracts of NaviCyte, nor has NaviCyte received notice or warning of
alleged nonperformance, delay in delivery or other noncompliance by NaviCyte or
any third party with respect to their respective obligations under any of those
contracts, nor are there any facts which exist indicating that any of those
contracts may be totally or partially terminated or suspended by the other
party(ies) thereto.
-18-
<PAGE> 19
(c) To the Best Knowledge of NaviCyte or the NaviCyte Majority
Stockholders, the provisions of any and all agreements to which NaviCyte is a
party or by which it is bound comply in all respects with the laws of applicable
jurisdictions. NaviCyte has performed all obligations required to be performed
by it and is not in default in any respect under any agreement, lease or other
instrument to which it is a party or by which it or its assets or properties are
bound; and no event has occurred which, with notice or lapse of time, or both,
would constitute such a default.
2.18 Proprietary Rights.
(a) SCHEDULE 2.18(a) attached hereto sets forth a true, correct
and complete list of any and all patents, patent applications, computer
programs, trade secrets, copyrights, inventions, drawings, designs, data,
trademarks, trade names, service marks, proprietary know-how, information and
any and all other rights which have been used in NaviCyte's business as it has
been conducted, which are being used in NaviCyte's business as it is now being
conducted or which NaviCyte presently contemplates using in NaviCyte's Proposed
Business (as defined below) (collectively, the "NAVICYTE PROPRIETARY RIGHTS").
Such list includes, as applicable:
(i) The title of the patent, mark or copyright, or patent,
mark or copyright application constituting such NaviCyte
Proprietary Right;
(ii) The jurisdictions by or in which such NaviCyte
Proprietary Right has been issued or registered or in which an
application for such issuance or registration has been filed or
is pending, including the respective registration or application
numbers; and
(iii) Material licenses, sublicenses, research agreements,
collaborations, joint development and similar agreements with
licensors, licensees or sublicensees as to which NaviCyte or any
of its affiliates is a party.
For purposes of this Section 2.18, NaviCyte's "PROPOSED BUSINESS" shall mean the
business of NaviCyte as it is assumed to be conducted in the financial
projections of NaviCyte which are attached hereto as SCHEDULE 2.18(b).
(b) Except as set forth on SCHEDULE 2.18(c) attached hereto,
NaviCyte owns exclusively (without any license to, right of or claim by any
third party) all of the NaviCyte Proprietary Rights. For each right listed
thereon, SCHEDULE 2.18(c) includes information regarding the owner of such
right, the terms under which NaviCyte utilizes such right and, to the Actual
Knowledge of NaviCyte or the NaviCyte Majority Stockholders, the claims or
rights of any third parties with respect to such right. With respect to the
rights listed on SCHEDULE 2.18(c) hereto, such rights are, to the Best Knowledge
of NaviCyte or the NaviCyte Majority Stockholders, free of any unresolved
ownership disputes or claims of any third party; and otherwise, the NaviCyte
Proprietary Rights are free of any such disputes or claims.
-19-
<PAGE> 20
(c) NaviCyte's rights under or to NaviCyte Proprietary Rights
constitute all rights (whether under or to patents, patent applications,
computer programs, trade secrets, copyrights, inventions, drawings, designs,
data, trademarks, trade names, service marks, proprietary know-how, information
or otherwise) necessary to conduct (i) the business of NaviCyte as it has been
conducted, (ii) the business of NaviCyte as it is now being conducted or (iii)
NaviCyte's Proposed Business (clauses (i), (ii) and (iii) being hereinafter
referred to as "NAVICYTE'S BUSINESS"); provided, however, that excluded from the
application of the foregoing clause (iii) are rights to claims under patents
issued in the United States to third parties after the Agreement Date to the
extent that such rights, claims or patents (and any associated applications)
were not known to NaviCyte or the NaviCyte Majority Stockholders as of the
Agreement Date and could not have been known (e.g., upon the review of any
publicly available information) as of the Agreement Date (with the rights that
are the subject of this proviso being hereinafter referred to as the "EXCLUDED
RIGHTS").
(d) To the Best Knowledge of NaviCyte or the NaviCyte Majority
Stockholders and except as set forth on SCHEDULE 2.18(d) attached hereto, there
is no unauthorized use, infringement or misappropriation of any NaviCyte
Proprietary Right by any third party (including, without limitation, any current
or former employee, officer, director, consultant or advisor of NaviCyte). None
of the NaviCyte Proprietary Rights has been a subject of any litigation or other
claim, action, dispute or proceeding regarding validity (whether currently
pending or concluded), nor, to the Actual Knowledge of NaviCyte or the NaviCyte
Majority Stockholders, is any such litigation or other claim, action, dispute or
proceeding threatened.
(e) NaviCyte has received from each current or former officer,
employee, advisor or consultant of NaviCyte an agreement providing NaviCyte with
title and ownership to all NaviCyte Proprietary Rights developed or held by such
individual, by assignment or otherwise, and NaviCyte owes no obligation to any
person or entity with respect thereto (including, without limitation, any
royalty payment obligation). Except as set forth on SCHEDULE 2.18(c), all of
such agreements are valid, enforceable and legally binding, subject to the
effect or availability of rules of law governing specific performance,
injunctive relief or other equitable remedies (regardless of whether any such
remedy is considered in a proceeding at law or in equity).
(f) No one has asserted to NaviCyte that NaviCyte's Business
(including, without limitation, its research and development strategies,
methods, processes and inventions) conflict with or infringe, and, to the Best
Knowledge of NaviCyte or the NaviCyte Majority Stockholders, NaviCyte's Business
does not conflict with or infringe, any Proprietary Rights (as defined below)
owned, possessed or used by any third party. There are no claims, disputes,
actions, proceedings, suits or appeals pending against NaviCyte with respect to
any Proprietary Rights (including, without limitation, the NaviCyte Proprietary
Rights) and, to the Actual Knowledge of NaviCyte or the NaviCyte Majority
Stockholders, none has been threatened. Except for the rights of third parties
listed on SCHEDULE 2.18(c) attached hereto and any Excluded Rights, there are no
facts or alleged facts which would reasonably serve as a basis for any claim
that NaviCyte does not have the right to use, free of any rights or claims of
others, any of the NaviCyte Proprietary Rights. For purposes of this Section
2.18, "PROPRIETARY
-20-
<PAGE> 21
RIGHTS" means any and all rights under or to patents, patent applications,
computer programs, trade secrets, copyrights, inventions, drawings, designs,
data, trademarks, trade names, service marks, proprietary know-how, information
or other rights.
(g) A list of any proceedings before any patent or trademark
authority to which NaviCyte is a party, a description of the subject matter of
each proceeding, and the current status of each proceeding, including, without
limitation, office actions, interferences, priority contests, oppositions and
protests, is attached hereto as SCHEDULE 2.18(e). Such list also includes any
pending applications for reissue or reexamination of a patent.
(h) NaviCyte has taken all commercially reasonable measures to
maintain the confidentiality of the processes and formulae, technical
strategies, methods, inventions, trade secrets, research and development results
and other know-how, the value of which to NaviCyte or Trega is contingent upon
maintenance of the confidentiality thereof.
(i) Each current and former employee, officer, consultant and
advisor of NaviCyte has executed a commercially reasonable and valid and
enforceable employee secrecy agreement. To the Best Knowledge of NaviCyte or the
NaviCyte Majority Stockholders, no current or former employee, officer,
consultant or advisor of NaviCyte is in violation of any term of any employment
contract, proprietary information and inventions agreement, non-competition
agreement, employee secrecy agreement or any other contract or agreement
relating to the relationship of any such person with NaviCyte or any previous
employer.
(j) Without limiting the foregoing: (i) with respect to each
patent which is included within the NaviCyte Proprietary Rights, there is no
basis for invalidating any claim therein and, to the Best Knowledge of NaviCyte
or the NaviCyte Majority Stockholders, no suggestion or assertion has been made
that any such claim is invalid or unenforceable; and (ii) with respect to each
patent application which is set forth on SCHEDULE 2.18(j) attached hereto: (A)
the patent applications listed on SCHEDULE 2.18(j) represent a complete list of
the patent applications in or to which NaviCyte has any right, title or
interest; (B) each such application has been properly prepared and filed and is
presently being diligently pursued by NaviCyte; (C) NaviCyte has the enforceable
right to receive assignment of the entire right, title and interest in and to
each such application from any and all inventors with respect thereto without
the payment of any further consideration whatsoever; and (D) to the Best
Knowledge of NaviCyte or the NaviCyte Majority Stockholders, (x) the claims set
forth in each such application contain patentable subject matter under
applicable laws (including, without limitation, in the United States) and (y) no
suggestion or assertion has been made that any such claim would, when a related
patent is issued, be invalid or unenforceable.
2.19 Insurance. NaviCyte has provided Trega with true, correct and
complete copies of all policies of insurance to which NaviCyte is a party or is
a beneficiary or named insured. A list of such policies is attached hereto as
SCHEDULE 2.19. NaviCyte has in full force and effect, with all premiums due
thereon paid, such policies of insurance. NaviCyte has received no notices of
cancellation, termination or non-renewal with respect to such policies. There
have been no claims asserted under any of the insurance policies of NaviCyte for
the period from NaviCyte's inception to the Effective Time.
-21-
<PAGE> 22
2.20 Bank Accounts. Attached hereto as SCHEDULE 2.20 is a true, correct
and complete list setting forth the names and addresses of all banks, other
institutions and state governmental departments at which NaviCyte has accounts,
money market accounts, deposits or safety deposit boxes, or special deposits
required to be held by such state governmental departments with the nature of
such account and the names of all persons authorized to draw on or give
instructions with respect to such accounts or deposits, or to have access
thereto, and the names and addresses of all persons, if any, holding a
power-of-attorney on behalf of NaviCyte. All cash in such accounts is held in
demand deposits and is not subject to any restriction or limitation as to
withdrawal.
2.21 Brokers or Finders. NaviCyte has not dealt with any broker or
finder in connection with the transactions contemplated by this Agreement.
NaviCyte has not incurred, and shall not incur, directly or indirectly, any
liability for any brokerage or finders' fees or agents' commissions or any
similar charges in connection with this Agreement or any transaction
contemplated hereby.
2.22 Certain Advances. There are no receivables of NaviCyte owing from
directors, officers, employees, consultants, advisors or stockholders of
NaviCyte, or owing by any affiliate of any director, officer or stockholder of
NaviCyte.
2.23 Related Parties. To the Best Knowledge of NaviCyte or the NaviCyte
Majority Stockholders, no officer, director, employee or securityholder of
NaviCyte, nor any member of any such person's immediate family, has, either
directly or indirectly, (a) an interest in or agreement with any corporation,
partnership, firm or other person or entity which competes, or, to the Actual
Knowledge of NaviCyte or the NaviCyte Majority Stockholders, which potentially
will compete, directly or indirectly, with NaviCyte, or (b) a beneficial
interest in any contract or agreement to which NaviCyte is a party or by which
NaviCyte may be bound. For purposes of this Section 2.23, there shall be
disregarded any interest which arose solely from the ownership of less than a
one percent (1%) equity interest in a corporation whose stock is regularly
traded on any national securities exchange or in the over-the-counter market.
2.24 Employees and Union Activities. NaviCyte has complied in all
material respects with all applicable state and federal laws related to
employment. None of NaviCyte's employees are represented by any union or are
parties to any collective bargaining arrangement, and, to the Actual Knowledge
of NaviCyte or the NaviCyte Majority Stockholders, no attempts are being made to
organize or unionize any of such employees.
2.25 ERISA.
(a) Attached hereto as SCHEDULE 2.25 is a list of each "employee
benefit plan," as defined in Section 3(3) of the Employee Retirement Income
Security Act of 1974, as amended ("ERISA"), and all other plans, agreements or
arrangements involving direct or indirect compensation (including any employment
agreements entered into between NaviCyte and any employee of NaviCyte, but
excluding worker's compensation, unemployment compensation and other
government-mandated programs) currently or previously maintained, contributed to
or entered into by NaviCyte or any ERISA Affiliate (defined below) thereof for
-22-
<PAGE> 23
the benefit of any employee or former employee of NaviCyte under which NaviCyte
or any ERISA Affiliate thereof has any present or future obligation or liability
(collectively, the "EMPLOYEE PLANS"). For purposes of this Section 2.25, "ERISA
Affiliate" shall mean any entity which is a member of (i) a "controlled group of
corporations," as defined in section 414(b) of the Code, (ii) a group of
entities under "common control," as defined in section 414(c) of the Code, (iii)
an "affiliated service group," as defined in section 414(m) of the Code, or (iv)
a group of entities aggregated under treasury regulations promulgated under
section 414(o) of the Code, any of which includes NaviCyte. Copies of all
Employee Plans (and, if applicable, related trust agreements), all amendments
thereto and all material written interpretations thereof, including (without
limitation) summary plan descriptions, have been provided to Trega, together
with (x) the most recent annual report (Form 5500), including if applicable,
Schedule B thereto prepared in connection with any such Employee Plan and (y)
the most recent actuarial valuation prepared in connection with any such
Employee Plan. SCHEDULE 2.25 attached hereto expressly identifies which of
NaviCyte's Employee Plans, individually or collectively, constitute an "employee
pension benefit plan" as defined in section 3(2) of ERISA (collectively, the
"PENSION PLANS").
(b) No Pension Plan is subject to Title IV of ERISA, Part 3 of
Subtitle B of Title I of ERISA or Section 412 of the Code. No Pension Plan
constitutes or has since the enactment of ERISA constituted a "multiemployer
plan," as defined in Section 3(37) of ERISA. No "prohibited transaction," as
defined in Section 406 of ERISA or Section 4975 of the Code, excluding
transactions effected pursuant to a statutory or administrative exemption, has
occurred with respect to any Employee Plan which is covered by Title I of ERISA
which would make NaviCyte or any officer or director thereof subject to any
liability under Title I of ERISA or liable for any tax pursuant to Section 4975
of the Code.
(c) Each Pension Plan which is intended to be qualified under
Section 401(a) of the Code is so qualified and has been so qualified during the
period from its adoption to date, except to the extent that the requirements for
qualification may be satisfied by adopting retroactive amendments under Section
401(b) of the Code and the regulations thereunder or under section 1140 of the
Tax Reform Act of 1986, and each trust forming a part of each such Pension Plan
is exempt from tax pursuant to Section 501(a) of the Code. NaviCyte has provided
to Trega copies of the most recent Internal Revenue Service determination
letters with respect to each such Pension Plan. Each Pension Plan has been
maintained in compliance with its terms and with the applicable requirements of
ERISA and the Code.
(d) To the extent not specifically referenced on another schedule
attached hereto, SCHEDULE 2.25 attached hereto includes a list and description
of each employment, severance or other similar contract, arrangement or policy
and each plan, agreement, policy or arrangement (written or oral) providing for
insurance coverage (including any self-insured arrangements), vacation benefits,
severance benefits, disability benefits, early retirement benefits, death
benefits, hospitalization benefits, retirement benefits, deferred compensation,
profit-sharing, bonuses, stock options, stock purchase, phantom stock, stock
appreciation or other forms of compensation or post-retirement benefits which
(i) is not an Employee Plan, (ii) is entered into, maintained or contributed to,
as the case may be, by NaviCyte and (iii) covers any employee or consultant or
former employee or consultant of NaviCyte. Such
-23-
<PAGE> 24
contracts, plans and arrangements as are described in this Section 2.25(d) are
herein referred to collectively as the "BENEFIT ARRANGEMENTS." Each Benefit
Arrangement has been maintained in compliance with its terms and with the
requirements prescribed by any and all statutes, orders, rules and regulations
which are applicable to such Benefit Arrangements, and Trega has been provided
with a copy of each such Benefit Arrangement.
(e) Except for standard employee salary increases in the ordinary
course of business, there has been no amendment to, written interpretation or
announcement (whether or not written) by NaviCyte relating to, or change in
employee participation or coverage under, any Employee Plan or Benefit
Arrangement which would increase the expense of maintaining such Employee Plan
or Benefit Arrangement above the level of the expense incurred in respect
thereof for the year ended December 31, 1997.
(f) NaviCyte has materially complied with the requirements of
section 4980B of the Code with respect to any "qualifying event" (as defined in
section 4980B(f)(3) of the Code) occurring prior to and including the Closing
Date, and no tax payable on account of Section 4980B of the Code has been
incurred with respect to any current or former employee of NaviCyte.
(g) NaviCyte is not a party to any contract, instrument,
agreement or arrangement with a "disqualified individual" (as defined in Section
280G(c) of the Code) that could result in a disallowance of the deduction for
any "excess parachute payment" (as defined in Section 280G(b)(i) of the Code) or
subject any such disqualified individual to the excise tax imposed under Section
4999 of the Code.
(h) Each Employee Plan or Benefit Arrangement complies in all
material respects with all applicable requirements of (i) the Age Discrimination
in Employment Act of 1967, as amended, and the regulations thereunder, and (ii)
Title VII of the Civil Rights Act of 1964, as amended, and the regulations
thereunder.
(i) There is no pending or, to the Actual Knowledge of NaviCyte
or the NaviCyte Majority Stockholders, threatened claim or litigation relating
to any Employee Plan or Benefit Arrangement.
-24-
<PAGE> 25
2.26 Copies of Certain Documents. Prior to the date hereof, NaviCyte has
delivered or made available to Trega true and complete copies of (i) all
documents relating to NaviCyte that Trega has requested and (ii) all other
documents that a reasonable investor purchasing the capital stock of NaviCyte
would view as material in evaluating an investment decision with respect
thereto. The minute books of NaviCyte made available to Trega and its counsel
for inspection contain full, complete and accurate records of all meetings and
other corporate actions taken by the directors and stockholders of NaviCyte and
accurately reflect all material actions and proceedings taken to date by
NaviCyte's stockholders, Board of Directors and committees. The stock record
books of NaviCyte reflect accurately all transactions in its capital stock.
2.27 Full Disclosure.
(a) Information. Any written information furnished by George M.
Grass, Ph.D. or Patrick J. Sinko, Ph.D. to Trega (including, without limitation,
information and financial data pertaining to NaviCyte as well as NaviCyte's
confidential business plan dated November 1997 as the financial information
therein has been modified by the projections of NaviCyte which are attached
hereto as SCHEDULE 2.18(b)) does not contain any untrue statement of a material
fact and does not omit to state any material fact necessary to make any
statement, in light of the circumstances under which such statement is made, not
misleading; provided, however, that for purposes of this Section 2.27(a), Trega
acknowledges and agrees that (i) any projections or estimates of future results
included in such information contain forward-looking statements that involve
risks and uncertainties, including whether research will be successful, whether
any collaborations or alliances will be agreed to, formed or expanded, whether
regulatory approvals can be obtained for products discovered and developed, if
any, whether products can be successfully marketed, and the impact of
competitive products and pricing, (ii) such forward-looking statements represent
solely the estimates of NaviCyte's management based on assumptions viewed by
such management to have been reasonable at the time such information was
prepared and (iii) actual results may differ materially from those projected.
(b) Collaboration Agreements/Proprietary Rights. Without limiting
the generality of the foregoing Subsection 2.27(a) or the other provisions of
this Article 2, NaviCyte has provided and/or disclosed to Trega (in the person
of Robert S. Whitehead or Richard A. Kaufman) all information, analyses and
materials (whether of NaviCyte or its officers or employees, any third party or
the officers or employees of such third party or any consultant, advisor,
government representative or official) with respect to (i) the consents or
agreements of NaviCyte with third parties and (ii) the NaviCyte Proprietary
Rights (including, without limitation, with respect to the patentability,
copyrightability or other similar protection with respect thereto, as
applicable, and any potential or actual infringement with the rights of any
third parties).
2.28 Information Statement and Other Information. On the date NaviCyte
mails to the NaviCyte stockholders its disclosure documents relating to the
Merger (collectively, the "MERGER INFORMATION STATEMENT"), if any, and on the
date consent is solicited from NaviCyte's stockholders (or a vote on the Merger
by NaviCyte's stockholders otherwise takes place), and
-25-
<PAGE> 26
as of the Effective Time, NaviCyte's Merger Information Statement will contain
all material statements which are required to be set forth therein in accordance
with any applicable federal or state securities or corporate laws; and at such
respective times, the Merger Information Statement will not include any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading in
light of the circumstances under which they were made. Notwithstanding the
foregoing, NaviCyte and the NaviCyte Majority Stockholders make no
representation or warranty in respect of any information supplied by Trega for
inclusion in the Merger Information Statement.
2.29 NaviCyte Affiliates. SCHEDULE 2.29 attached hereto includes a list
of each person who, as of the date hereof, may be deemed to be an "affiliate" of
NaviCyte as that term is used in Rule 145 under the Securities Act of 1933, as
amended (the "1933 ACT"), and the rules and regulations thereunder and who will
become a beneficial owner of Trega Common Stock pursuant to the Merger (the
"NAVICYTE AFFILIATES").
2.30 Discussions. SCHEDULE 2.30 attached hereto includes a list of each
Discussion (as defined in Section 4.3(b) below) as of the date hereof.
2.31 Withholding. With respect to the grant or exercise of any and all
NaviCyte Options prior to or in connection with the Merger or the Closing,
NaviCyte has made all necessary or appropriate arrangements with respect to the
withholding of appropriate amounts from each respective optionee (e.g., pursuant
to obligations regarding income and employment taxes). In any instance where
withholding has not been effected in connection with the grant or exercise of
any NaviCyte Option, neither Trega, NaviCyte nor the Surviving Corporation shall
have any liability whatsoever with respect thereto.
2.32 Rutgers. Without limiting the other provisions of this Agreement or
the provisions of the Employment Agreement in the form attached hereto as
EXHIBIT E-2, the relationship of Patrick J. Sinko, Ph.D. to NaviCyte prior to
the date hereof (including, without limitation, the performance by Dr. Sinko of
any employment or consulting agreements) and the performance by Dr. Sinko of the
Employment Agreement in the form attached hereto as EXHIBIT E-2 (i) to the Best
Knowledge of NaviCyte or the NaviCyte Majority Stockholders have not and do not
violate, in any way, any agreements or other arrangements between or involving
Dr. Sinko and Rutgers, the State University of New Jersey ("RUTGERS"), as the
same may have been in existence prior to the date hereof or as the same may
presently be in existence, (ii) to the Actual Knowledge of NaviCyte or the
NaviCyte Majority Stockholders have not and do not violate, in any way, any
policies, regulations or arrangements of any institution or entity binding upon
or applicable to Dr. Sinko (including, without limitation, Rutgers), as the same
may have been in existence prior to the date hereof or as the same may presently
be in existence, and (iii) have not and shall not, in any way, engender or
create in or for Rutgers or any other institution or entity any right in or to
any NaviCyte Proprietary Rights.
-26-
<PAGE> 27
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF
TREGA AND ACQUISITION CORPORATION
Except as otherwise set forth in SCHEDULE 4 (the "TREGA DISCLOSURE
SCHEDULE") delivered to NaviCyte prior to the execution of this Agreement and
attached hereto (it being agreed that for any item set forth in the Trega
Disclosure Schedule having relevance to more than one of the following sections
of this Article 3, disclosure in any one section shall constitute disclosure for
purposes of all applicable sections of the Trega Disclosure Schedule), each of
Trega and Acquisition Corporation represent and warrant to NaviCyte as follows:
3.1 Organization. Each of Trega and Acquisition Corporation (a) is a
corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware, (b) is duly qualified to do business and is in
good standing in each jurisdiction in which it owns or leases property or
conducts business, except where the failure to be so qualified would not have a
material adverse effect on the business of Trega and (c) has all requisite
corporate power and authority to own, lease and operate its properties and to
carry on its business as now being conducted.
3.2 Authority.
(a) Each of Trega and Acquisition Corporation has all requisite
corporate power and authority to enter into this Agreement and the related
agreements contemplated herein, and, subject to satisfaction of the conditions
set forth herein, to consummate the transactions contemplated hereby and
thereby. The execution and delivery of this Agreement and the related agreements
contemplated hereby and the consummation of the transactions contemplated hereby
and thereby have been duly authorized by all necessary corporate action on the
part of Trega and Acquisition Corporation. This Agreement and the related
agreements contemplated hereby have been duly executed and delivered by each of
Trega and Acquisition Corporation and constitute valid and binding obligations
of Trega and Acquisition Corporation, enforceable in accordance with their
terms, subject to (i) the effect of applicable bankruptcy, insolvency,
reorganization, moratorium or other similar federal or state laws affecting the
rights of creditors and (ii) the effect or availability of rules of law
governing specific performance, injunctive relief or other equitable remedies
(regardless of whether any such remedy is considered in a proceeding at law or
in equity). Provided the conditions set forth in Article 5 are satisfied, the
execution and delivery of this Agreement and the related agreements contemplated
hereby do not, and the consummation of the transactions contemplated hereby will
not, conflict with or result in any violation of or default (with or without
notice or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation or to loss of a material benefit,
or result in the creation of any lien, encumbrance or restriction in favor of
any third party upon any of the assets or properties of Trega, under (a) any
provision of the Certificate of Incorporation or Bylaws of Trega, (b) any
provision of the Articles of Incorporation or Bylaws of Acquisition Corporation,
(c) any agreement or instrument, permit, license, judgment or order applicable
to Trega or Acquisition Corporation or their respective properties or assets or,
(d) to the Best Knowledge of Trega, any local, state,
-27-
<PAGE> 28
federal or foreign statute, law, ordinance, rule or regulation applicable to
Trega or Acquisition Corporation or their respective properties or assets, other
than any such conflicts, violations, defaults, terminations, cancelations or
accelerations which individually or in the aggregate would not have a material
adverse effect on the assets, business or results of operations of Trega.
(b) No consent, approval, order or authorization of, or
registration, declaration or filing with, any Governmental Entity or other
person is required by or with respect to Trega or Acquisition Corporation in
connection with the execution and delivery of this Agreement or the related
agreements contemplated hereby by Trega and Acquisition Corporation or the
consummation by Trega and Acquisition Corporation of the transactions
contemplated hereby, except for (a) the filing of the Delaware Certificate of
Merger with the Delaware Secretary of State, (b) such consents, approvals,
orders, authorizations, registrations, declarations and filings as may be
required under applicable federal or state securities laws (including, without
limitation, the filing of a Form D with the SEC with reference to Section 4.9
below) and (c) such other consents, authorizations, filings, approvals and
registrations which if not obtained or made would not have a material adverse
effect on the assets, business or results of operations of Trega.
3.3 Capital Structure.
(a) The authorized capital stock of Trega consists of 40,000,000
shares of Trega Common Stock and 5,000,000 shares of preferred stock, $.001 par
value ("TREGA PREFERRED STOCK"). At the close of business on November 2, 1998:
(i) approximately 13,995,461 shares of Trega Common Stock were issued and
outstanding; (ii) up to approximately 4,960,465 shares of Trega Common Stock
were reserved (or available) for issuance upon the exercise of options granted
(or available for grant) by Trega under its 1992, 1995 or 1996 Stock Plans
("TREGA OPTIONS"); and (iii) up to approximately 250,000 shares of Trega Common
Stock were reserved for issuance under the Trega 1996 Employee Stock Purchase
Plan. No shares of Trega Preferred Stock are outstanding.
(b) The authorized capital stock of Acquisition Corporation
consists of 1,000 shares of common stock, of which, as of the date of this
Agreement, 100 shares are issued and outstanding and held by Trega.
(c) Except as contemplated by this Agreement, as set forth on
SCHEDULE 4 attached hereto or as referenced in the Trega SEC Documents (defined
below), as of the date of this Agreement there are no options, warrants or other
rights, agreements, arrangements or commitments relating to the issued or
unissued capital stock of Trega or any subsidiary of Trega, including
Acquisition Corporation (each a "Trega Subsidiary"), obligating Trega or any
Trega Subsidiary to issue or sell any shares of capital stock of, or other
equity interests in, Trega or any Trega Subsidiary. Between June 30, 1998, and
the date of this Agreement, no shares of Trega Common Stock have been issued by
Trega, except pursuant to the options, warrants or other rights, agreements,
arrangements and commitments described in SCHEDULE 4 or referenced in the Trega
SEC Documents (including the exhibits thereto), in each case in accordance with
their respective terms.
-28-
<PAGE> 29
(d) There are no outstanding contractual obligations of Trega or
any Trega Subsidiary to repurchase, redeem or otherwise acquire any shares of
Trega Common Stock, or any capital stock of, or any equity interests in, any
Trega Subsidiary. Prior to the date hereof, Trega has made available to NaviCyte
true and correct copies of all agreements to which Trega is a party pursuant to
which holders of Trega securities have been granted any registration rights in
respect thereof.
3.4 SEC Documents.
(a) Trega has filed all reports required to be filed by it with
the Securities and Exchange Commission (the "SEC") since June 30, 1997, and
Trega has furnished, or made available to NaviCyte, true, correct and complete
copies of Trega's Annual Report on Form 10- K for the year ended December 31,
1997 and Trega's Quarterly Report on Form 10-Q for the quarter ended June 30,
1998 (collectively, the "TREGA SEC DOCUMENTS"). As of their respective dates,
each Trega SEC Document complied in all material respects with the applicable
requirements of the Securities Exchange Act of 1934, as amended (the "1934
ACT"), and none of the Trega SEC Documents, as of their respective dates,
contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements
made therein, in light of the circumstances under which they were made, not
misleading.
(b) Each of the audited consolidated financial statements
(including, in each case, any notes thereto) contained in the Trega SEC
Documents was prepared in accordance with GAAP throughout the periods indicated.
Each of the consolidated financial statements (including, in each case, any
notes thereto) contained in the Trega SEC Documents fairly presented in all
material respects the consolidated financial position, results of operations and
changes in stockholders' equity and cash flows of Trega and its consolidated
subsidiaries as at the respective dates thereof and for the respective periods
indicated therein (subject, in the case of unaudited statements, to (i) normal
year-end adjustments which are not expected, individually or in the aggregate,
to be material and (ii) the absence of all GAAP notes to such financial
statements).
(c) Except (i) to the extent set forth on the balance sheet of
Trega as at June 30, 1998, including the notes thereto (the "TREGA BALANCE
SHEET"), (ii) as set forth on SCHEDULE 4 attached hereto or (iii) as disclosed
in any Trega SEC Document, Trega does not have any liability or obligation of
any nature (whether accrued, absolute, contingent or otherwise) which would be
required to be reflected on a balance sheet, or in the notes thereto, prepared
in accordance with GAAP which would have a material adverse effect on the
assets, business or results of operations of Trega, except for liabilities and
obligations incurred in the ordinary course of business consistent with past
practice since December 31, 1997.
(d) With respect to those agreements, documents and other
instruments that have been filed by Trega as exhibits to Trega SEC Documents and
that are material to Trega's business as of the date of this Agreement, Trega
has made available to NaviCyte complete and correct copies of all material
amendments and modifications thereto (if any) that have not been filed by Trega
with the SEC.
-29-
<PAGE> 30
3.5 Shares of Common Stock. The shares of Trega Common Stock to be
issued and delivered to the NaviCyte securityholders as of the Effective Time
(the "NAVICYTE SECURITYHOLDERS") in accordance with this Agreement, when so
issued and delivered, will (a) be duly authorized, validly issued, fully paid
and nonassessable and not subject to preemptive rights created by statute,
Trega's Certificate of Incorporation or Bylaws or any agreement to which Trega
is a party, and (b) based in part upon the representations of the NaviCyte
Securityholders and the covenants of NaviCyte, be issued pursuant to available
and valid exemptions from the registration and qualification provisions of
applicable federal and state securities laws.
3.6 Absence of Certain Changes or Events. Since June 30, 1998, except as
contemplated by or disclosed pursuant to this Agreement (including, without
limitation, SCHEDULE 4 attached hereto), any writing delivered by Trega to
NaviCyte on or prior to the date hereof or any Trega SEC Document, Trega has
conducted its businesses only in the ordinary course and in a manner consistent
with past practice and, since June 30, 1998, there has not been (a) any event or
events (whether or not covered by insurance), individually or in the aggregate,
having a material adverse effect on the business, assets or results of
operations of Trega, (b) any material change by Trega in its accounting methods,
principles or practices, (c) any entry by Trega or any Trega Subsidiary into any
commitment or transaction material to Trega, except in the ordinary course of
business and consistent with past practice, (d) any declaration, setting aside
or payment of any dividend or distribution in respect of any capital stock of
Trega or any redemption, purchase or other acquisition of any of Trega's
securities, or (e) any agreement or arrangements made by the Trega or any Trega
Subsidiary to take any action which, if taken prior to the date hereof, would
have made any representation or warranty set forth in this Section 3.6 untrue or
incorrect as of the date when made.
3.7 Absence of Litigation. Except as disclosed on SCHEDULE 4 attached
hereto or in any Trega SEC Document, there is no claim, action, proceeding or
investigation pending or, to the Actual Knowledge of Trega, threatened against
Trega or any Trega Subsidiary, before any arbitrator or governmental authority,
which, individually or in the aggregate, would reasonably be expected to have a
material adverse effect on the assets, business or results of operations of
Trega. Neither Trega nor any Trega Subsidiary, nor any property or asset of
Trega or any Trega Subsidiary, is in violation of any order, writ, judgment,
injunction, decree, determination or award having, individually or in the
aggregate, a material adverse effect on the assets, business or results of
operations of Trega.
3.8 Copies of Certain Documents. Prior to the date hereof, Trega has
delivered or made available to NaviCyte true and complete copies of all material
documents relating to Trega that NaviCyte has requested.
3.9 Brokers or Finders. Except for any financial advisor engaged to
render an opinion or to advise Trega with respect to the transactions
contemplated by this Agreement, Trega has not (i) dealt with any broker or
finder in connection with the transactions contemplated by this Agreement nor
(ii) incurred, directly or indirectly, any liability for any brokerage or
finders' fees or agents' commissions or any similar charges in connection with
this Agreement or any transaction contemplated hereby.
-30-
<PAGE> 31
3.10 Information. Any written information furnished by any member of
Trega's management to NaviCyte does not contain any untrue statement of a
material fact and does not omit to state any material fact necessary to make any
statement, in light of the circumstances under which such statement is made, not
misleading; provided, however, that for purposes of this Section 3.10, NaviCyte
acknowledges and agrees that (i) any projections or estimates of future results
included in such information contain forward-looking statements that involve
risks and uncertainties, including those risks and factors identified in the
Trega SEC Documents, (ii) such forward-looking statements represent solely the
estimates of Trega's management based on assumptions viewed by such management
to have been reasonable at the time such information was prepared and (iii)
actual results may differ materially from those projected.
ARTICLE 4
ADDITIONAL AGREEMENTS
4.1 Legal Conditions to the Merger. Each Party will take all reasonable
actions (a) necessary to comply promptly with all legal requirements which may
be imposed on such Party with respect to the Merger and will promptly cooperate
with and furnish information to the other Parties hereto in connection with any
such requirements imposed upon the other Parties in connection with the Merger
and (b) to obtain (and to cooperate with the other Parties, if any, in
obtaining) any consent, authorization, order or approval of, or any exemption
by, any governmental authority, or other third party, required to be obtained or
made by such Party, if any (or by the other Parties), in connection with the
Merger or the taking of any action contemplated thereby or by this Agreement.
4.2 NaviCyte Stockholders' Approval.
(a) NaviCyte agrees to use its best efforts promptly to (i)
submit this Agreement and any related matters to its stockholders for approval,
by means of the Merger Information Statement, all as provided by law and the
NaviCyte Charter and the NaviCyte Bylaws, by unanimous written consent as soon
as practicable after the date of this Agreement, and (ii) obtain the approval of
all NaviCyte stockholders to the Merger as contemplated herein.
(b) Trega shall furnish NaviCyte with all non-confidential
information concerning its operations as NaviCyte may reasonably request in
connection with the preparation of the Merger Information Statement. Trega
represents and warrants to NaviCyte that the information supplied by Trega for
inclusion in the Merger Information Statement, when considered together with any
Supplemental Information (defined below), shall not, at (i) the time the Merger
Information Statement is first mailed to the NaviCyte stockholders, (ii) the
time that NaviCyte's stockholders consent to the Merger and (iii) the Effective
Time, contain any statement which, at such time and in light of the
circumstances under which it is made, is false or misleading with respect to any
material fact, or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein not false or misleading
with respect to any material fact. Without limiting the right of NaviCyte to
rely on the accuracy of the representations and warranties of Trega as set forth
in this Agreement, if, at any
-31-
<PAGE> 32
time prior to the Effective Time, any event or circumstance relating to Trega or
its officers or directors is discovered by Trega and determined by Trega to be
appropriate for distribution as an amendment or a supplement to the Merger
Information Statement, Trega shall promptly inform NaviCyte (collectively
referred to herein as "SUPPLEMENTAL INFORMATION").
(c) Each of the NaviCyte Majority Stockholders agrees to approve
the Merger as contemplated herein, and NaviCyte agrees to solicit such approval
from all other NaviCyte stockholders.
(d) The Corporate Parties and their counsel will promptly prepare
the Merger Information Statement. Each Corporate Party shall take all
commercially reasonable actions to provide appropriate information regarding
such Corporate Party and the transactions contemplated hereby for inclusion in
the Merger Information Statement.
4.3 Interim Operations of NaviCyte.
(a) NaviCyte covenants and agrees that, prior to the Effective
Time (unless Trega shall otherwise agree in writing):
(i) Its business shall be conducted only in the ordinary
and usual course.
(ii) It shall use its best efforts to preserve its
business organization intact and maintain its existing relations with
customers, suppliers, employees and business associates.
(iii) It shall not (A) create any subsidiaries; (B) amend
the NaviCyte Charter or the NaviCyte Bylaws; (C) split, combine or
reclassify its capital stock; or (D) declare, set aside or pay any
dividend payable in cash, stock or property with respect to its capital
stock.
(iv) It shall not (A) issue, sell, pledge, dispose of or
encumber any shares of, or securities convertible or exchangeable for,
or options, warrants, calls, commitments or rights of any kind to
acquire any shares of, its capital stock of any class or any other
property or assets other than shares issuable upon the exercise of
outstanding NaviCyte Options as expressly identified above (in Section
2.2); (B) transfer, lease, license, guarantee, sell, mortgage, pledge,
dispose of or encumber any assets or properties (including, without
limitation, any Proprietary Rights); (C) incur or modify any
indebtedness or other Liability other than in the ordinary and usual
course of business; (D) acquire, directly or indirectly by redemption or
otherwise, any shares of its capital stock; or (E) authorize capital
expenditures in excess of $10,000.00 (in the aggregate) or make any
acquisition of, or investment in, assets or stock of any other person or
entity.
-32-
<PAGE> 33
(v) It shall not commit to or effect any licensing
arrangement (inbound or outbound), corporate partnering or collaboration
agreement, research and development agreement or any similar agreement
or arrangement with any third party.
(vi) It shall not grant any severance or termination pay
to, or enter into any employment or severance agreement with, any
director, officer, employee or consultant; and it shall not establish,
adopt, enter into, make any new grants or awards under or amend any
collective bargaining, bonus, profit sharing, thrift, compensation,
stock option, restricted stock, pension, retirement, employee stock
ownership, deferred compensation, employment, termination, severance or
other plan, agreement, trust, fund, policy or arrangement for the
benefit of any director, officer, employee or consultant.
(vii) It shall not settle or compromise any material
claims or litigation or modify, amend or terminate any of its contracts
or agreements or waive, release or assign any material rights or claims.
(viii) It shall not make any tax election or permit any
insurance policy naming it as a beneficiary or a loss payable payee to
be canceled or terminated.
(ix) It shall not authorize or enter into any agreement or
arrangement to do any of the foregoing, or, except as expressly
permitted pursuant to the provisions of Section 4.3(b) below, negotiate,
hold discussions with respect to, or otherwise take any actions
regarding any of the foregoing.
(b) On or prior to the date hereof, NaviCyte shall advise Trega
regarding all of its negotiations or discussions with any third party regarding
any activity contemplated by Section 4.3(a) above (collectively, the
"DISCUSSIONS"). In Trega's sole discretion, Trega may notify NaviCyte in writing
to discontinue any such Discussions or to continue such Discussions only on
terms approved by Trega (in its sole discretion). In the absence of such written
notice, NaviCyte may further pursue such Discussions (although the consummation
of any transaction or arrangement with respect thereto shall require Trega's
consent as provided in Section 4.3(a) above).
4.4 Access. Subject to the terms and conditions of that certain
Confidentiality and Standstill Agreement between Trega and NaviCyte dated June
22, 1998 (the "CONFIDENTIALITY AGREEMENT"), and upon reasonable notice, NaviCyte
shall afford the officers, employees, counsel, accountants and other authorized
representatives (collectively, "REPRESENTATIVES") of Trega access, during normal
business hours throughout the period prior to the Effective Time, to its
properties, books, contracts, agreements and records and, during such period,
NaviCyte shall furnish promptly to Trega all information concerning its
business, properties and personnel as Trega or its Representatives may
reasonably request. Without limiting the foregoing, NaviCyte shall prepare and
provide Trega with monthly (unaudited) financial statements promptly following
the end of each calendar month from and after the date of this Agreement and
until the Closing or the termination of this Agreement.
-33-
<PAGE> 34
4.5 Good Faith. Each Party shall act in good faith (a) in an attempt to
cause to be satisfied all the conditions precedent to its obligations and those
of the other Parties to this Agreement over which it has control or influence
and (b) take all reasonable action within its capability necessary to render
accurate as of the Effective Time its representations and warranties contained
in this Agreement.
4.6 State Statutes. If any state takeover law shall become applicable to
the transactions contemplated by this Agreement, Trega and its Board of
Directors or NaviCyte and its Board of Directors, as the case may be, shall use
their reasonable efforts to obtain such approvals and take such actions as are
necessary so that the transactions contemplated by this Agreement may be
consummated as promptly as practicable on the terms contemplated by this
Agreement and otherwise to minimize the effects of such state takeover law on
the transactions contemplated by this Agreement.
4.7 Update to Disclosures. Without limiting a Party's right to rely on
the representations and warranties of the other Party(ies) as of the date of
this Agreement, each Party shall provide updates to the disclosures provided or
made available hereunder as to material facts which arise between the date of
this Agreement and the Closing Date and which, if they had occurred prior to the
date of this Agreement, would have been required to have been disclosed in order
to make the representations and warranties contained in Article 2 or 3, as the
case may be, true and correct as of the date of this Agreement.
4.8 No Solicitation. Unless and until this Agreement shall have been
terminated pursuant to Article 7 hereof, neither NaviCyte nor any of its
officers, directors or affiliates nor any of the NaviCyte Majority Stockholders
shall initiate contact with, solicit or encourage any inquiry or proposal by, or
enter into discussions with, or disclose, directly or indirectly, any
information not customarily disclosed to the public concerning the business and
properties of NaviCyte to, or afford access to the properties, books or records
of NaviCyte to, any corporation, partnership, company, person or other entity or
group in connection with any possible proposal (an "ACQUISITION PROPOSAL")
regarding a sale of any of NaviCyte's capital stock or a merger, consolidation,
sale of all or a substantial portion of the assets of NaviCyte or any similar
transaction. NaviCyte will notify Trega promptly if any discussions or
negotiations are sought to be initiated, any inquiry or proposal is made, or any
such information is requested with respect to an Acquisition Proposal or
potential Acquisition Proposal or if any Acquisition Proposal is received or
indicated to be forthcoming.
4.9 Exempt Transaction. Each party shall take all actions necessary or
advisable for the issuances of shares of Trega Common Stock in connection with
the Merger to qualify as a transaction exempt from the registration provisions
of Section 5 of the 1933 Act pursuant to Rule 506 of Regulation D promulgated
thereunder ("REGULATION D"). In connection with the distribution of the Merger
Information Statement, NaviCyte agrees to cause each NaviCyte Securityholder
(including, without limitation, the holders of NaviCyte Options) to complete (i)
a Prospective Investor Questionnaire in the form attached hereto as EXHIBIT D-1
(a "QUESTIONNAIRE") and (ii) an investment representation letter in the form
attached hereto as EXHIBIT D-2 (a "REPRESENTATION LETTER"). To the extent that
any Corporate Party or counsel for any Corporate Party reasonably determines
that a holder of NaviCyte Common Stock is not
-34-
<PAGE> 35
sophisticated for purposes of Rule 506 of Regulation D, NaviCyte agrees that it
shall retain a "PURCHASER REPRESENTATIVE" (as defined in Rule 501 of Regulation
D) to assist such holder(s) in evaluating the Merger Information Statement and
the investment decision represented by this Agreement and the transactions
contemplated hereby (including, without limitation, the Merger).
4.10 Registration Rights. The former stockholders of NaviCyte receiving
Current Shares and Escrow Shares in connection with the Merger shall have such
registration rights with respect thereto as are set forth on SCHEDULE 5 attached
hereto; provided, however, that such stockholders shall agree to be bound by the
provisions of such SCHEDULE 5 as a condition precedent to the enjoyment of any
such rights and, at the request of Trega, any such stockholder shall execute a
specific acknowledgement and agreement to be so bound (or else such stockholder
shall be deemed to have forfeited such rights).
4.11 Third Party Guaranties. Promptly following the Effective Time,
Trega shall exercise its commercially reasonably efforts to displace George M.
Grass, Ph.D. as the guarantor of those certain obligations which are expressly
identified on SCHEDULE 4.11 attached hereto. In the event that Trega is unable
so to displace Dr. Grass, Trega shall indemnify and hold Dr. Grass harmless from
any liabilities which Dr. Grass may reasonably incur as the result of his status
as the guarantor of such obligations.
ARTICLE 5
CONDITIONS PRECEDENT
5.1 Conditions to Obligations of the Corporate Parties to Effect the
Merger. The obligations of the Corporate Parties to effect the Merger shall be
subject to the satisfaction on or prior to the Closing Date of the following
conditions unless waived by each of the Corporate Parties:
(a) Legal Action. No temporary restraining order, preliminary
injunction or permanent injunction or other order preventing the consummation of
the Merger shall have been issued by any federal or state court and remain in
effect, and no litigation seeking the issuance of such an order or injunction
shall be pending which, in the good faith judgment of NaviCyte or Trega, has a
reasonable probability of resulting in such order, injunction or damages. In the
event any such order or injunction shall have been issued, each Party agrees to
use its reasonable efforts to have any such injunction lifted.
(b) Statutes. No statute, rule or regulation shall have been
enacted by any Governmental Entity which would (i) make the consummation of the
Merger illegal, (ii) prohibit Trega's or the Surviving Corporation's ownership
or operation of all or a material portion of the business or assets of NaviCyte,
or compel Trega or the Surviving Corporation to dispose of or hold separate all
or a material portion of the business or assets of NaviCyte as a result of the
Merger, or (iii) render any Corporate Party unable to consummate the Merger,
except for any waiting period provisions.
-35-
<PAGE> 36
(c) Certificate of Merger. The Delaware Certificate of Merger
shall be fully executed and in the possession of Trega's agent for filing in
Delaware promptly following the Closing.
5.2 Conditions to Obligations of Trega and Acquisition Corporation. The
obligations of Trega and Acquisition Corporation to effect the Merger are
subject to the satisfaction on or prior to the Closing Date of the following
additional conditions, unless waived by Trega:
(a) Representations and Warranties. The representations and
warranties of NaviCyte and the NaviCyte Majority Stockholders set forth in this
Agreement shall be true, correct and complete in all respects as of the Closing
Date, except as otherwise specified by this Agreement, and Trega shall have
received a certificate or certificates to such effect signed by (i) the Chief
Executive Officer, the President and the Secretary of NaviCyte (the "NAVICYTE
OFFICERS") and (ii) each of the NaviCyte Majority Stockholders.
(b) Performance of Obligations of NaviCyte. NaviCyte shall have
performed in all respects all obligations required to be performed by it under
this Agreement prior to the Closing Date, and Trega shall have received a
certificate to such effect signed by the NaviCyte Officers.
(c) Stockholder Approval. This Agreement shall have been approved
and adopted by the unanimous affirmative vote or the unanimous written consent
of the holders of the outstanding shares of NaviCyte Common Stock.
(d) Employment Agreements.
(i) George M. Grass, Ph.D., shall have executed and
delivered to NaviCyte (and/or Trega, if applicable) the Employment
Agreement in the form attached hereto as EXHIBIT E-1.
(ii) Patrick J. Sinko, Ph.D., shall have executed and
delivered to NaviCyte (and/or Trega, if applicable) the Employment
Agreement in the form attached hereto as EXHIBIT E-2.
(e) NaviCyte Options. Each holder of a NaviCyte Option shall have
executed (i) a release regarding any and all rights with respect thereto and
(ii) an acknowledgement of receipt, to be effective promptly following the
Effective Time, of a Trega Substitute Option pursuant to SCHEDULE 2 attached
hereto.
(f) Questionnaires and Representation Letters. Trega shall have
received a copy of a Questionnaire and a Representation Letter, each completed
to the reasonable satisfaction of Trega and its counsel, from each holder of
NaviCyte Securities.
(g) Government Approvals. All authorizations, consents, orders or
approvals of, or declarations or filings with, or expiration of waiting periods
imposed by, any Governmental Entity necessary for the consummation of the
transactions contemplated by this
-36-
<PAGE> 37
Agreement (including, without limitation, any such requirements under applicable
federal or state securities laws) shall have been filed, occurred or been
obtained, other than filings with and approvals by any Governmental Entities
relating to the Merger if failure to make such filings or obtain such approvals
would not be materially adverse to Trega.
(h) Third-Party Approvals. Any and all notices to or consents or
approvals required from third parties in order to consummate the transactions
contemplated herein relating to contracts, agreements, licenses, leases and
other instruments material to the business of NaviCyte shall have been given or
obtained, as the case may be.
(i) Opinion of NaviCyte's Counsel. Trega shall have received the
legal opinion of counsel to NaviCyte dated as of the Closing and substantially
in the form attached hereto as EXHIBIT F.
(j) Resignation of NaviCyte Board. Except as otherwise
contemplated by Section 1.4(c), each director of NaviCyte shall have submitted
his resignation to be effective as of the Effective Time.
(k) Absence of Dissenting NaviCyte Shares. There shall be no
Dissenting NaviCyte Shares.
(l) Ratification of Prior Corporate Actions. The Board of
Directors and the stockholders of NaviCyte shall have adopted resolutions
ratifying, confirming and approving all actions taken by NaviCyte and its
officers (including, without limitation, (i) all issuances of NaviCyte Common
Stock, (ii) all grants of rights or options to purchase NaviCyte Common Stock
and (iii) the election and ratification of the past acts of all officers), and
Trega shall have received a certificate to such effect executed by the NaviCyte
Officers.
(m) [RESERVED]
(n) Termination of Royalty. George M. Grass, Ph.D., shall have
executed and delivered to each of NaviCyte and Trega confirmation of (i) the
termination of any entitlement of Dr. Grass (as well as any successors or
assigns of Dr. Grass) to receive any royalties or other similar payments from
NaviCyte (including, without limitation, as provided in that certain Technology
Assignment Agreement effective as of October 1, 1996) and, (ii) except as set
forth on SCHEDULE 5.2(n) attached hereto, the absence of any unpaid or
unperformed liabilities or obligations owed to Dr. Grass (as well as any
successors or assigns of Dr. Grass) for any reason whatsoever.
(o) Withholding Obligations. With respect to the grant or
exercise of any NaviCyte Options prior to or in connection with the Merger or
the Closing, NaviCyte shall have made all necessary or appropriate arrangements
with respect to the withholding of appropriate amounts from the respective
optionees (e.g., pursuant to obligations regarding income and employment taxes).
In the event that NaviCyte elects not to effect withholding with respect to the
grant or exercise of any particular NaviCyte Option, then NaviCyte shall provide
Trega with evidence reasonably satisfactory to Trega as to why withholding is
not required or advisable.
-37-
<PAGE> 38
In this regard, the Parties acknowledge that the labeling of any NaviCyte Option
as having been granted in compliance with the provisions of Section 422 of the
Internal Revenue Code of 1986, as amended (i.e., as an "incentive stock
option"), shall not be determinative of NaviCyte's withholding obligations.
(p) [RESERVED]
5.3 Conditions to Obligations of NaviCyte. The obligations of NaviCyte
and the Majority NaviCyte Stockholders to effect the Merger are subject to the
satisfaction on or prior to the Closing Date of the following additional
conditions unless waived by NaviCyte or the Majority NaviCyte Stockholders, as
the case may be:
(a) Representations and Warranties. The representations and
warranties of Trega and Acquisition Corporation set forth in this Agreement
shall be true, correct and complete in all respects as of the Closing Date,
except as otherwise contemplated herein or therein, and NaviCyte shall have
received a certificate signed by the Chief Executive Officer or Chief Financial
Officer of Trega (a "TREGA OFFICER") and by any executive officer of Acquisition
Corporation (an "A/C OFFICER") to such effect.
(b) Performance of Obligations of Trega and Acquisition
Corporation. Trega and Acquisition Corporation shall have performed in all
respects all obligations required to be performed by them under this Agreement
prior to the Closing Date, and NaviCyte shall have received a certificate signed
by a Trega Officer and an A/C Officer to such effect.
(c) Opinion of Trega's Counsel. NaviCyte shall have received the
legal opinion of counsel to Trega dated as of the Closing and substantially in
the form attached hereto as EXHIBIT G.
(d) Trading. There shall not have occurred and be in effect at
the Effective Time any suspension in trading of shares of Trega on the Nasdaq
National Market.
(e) Employment Agreements. NaviCyte (and/or Trega, if applicable)
shall have executed and delivered (i) to George M. Grass, Ph.D., the Employment
Agreement in the form attached hereto as EXHIBIT E-1, and (ii) to Patrick J.
Sinko, Ph.D., the Employment Agreement in the form attached hereto as EXHIBIT
E-2.
ARTICLE 6
OFFSET/INDEMNIFICATION
6.1 Offset.
(a) Offset Right. Trega and its successors and assigns shall be
entitled to recover (the "OFFSET RIGHT") against the Escrow Shares (including,
without limitation, any shares issued or issuable as Escrow Shares upon the
exercise of any Trega Substitute Option
-38-
<PAGE> 39
pursuant to the provisions of SCHEDULE 2 hereto) any and all losses,
liabilities, taxes, claims, suits, proceedings, demands, judgments, damages,
expenses and costs, including, without limitation, reasonable counsel fees,
costs and expenses incurred in the investigation, defense or settlement of any
claims (collectively, "DAMAGES"), which Trega or the Surviving Corporation may
suffer or incur (including, without limitation, as a result of a decrease in or
adverse effect upon the value of Trega's investment or ownership interest in the
Surviving Corporation) to the extent of and by reason of the inaccuracy or
breach of any of the representations, warranties, covenants or agreements of
NaviCyte contained in this Agreement or any documents, certificates or
agreements delivered pursuant hereto; provided, however, that (i) no Damages
shall be recognized for purposes of the Offset Right unless and until total
Damages exceed $30,000.00 (at which point all Damages shall be recognized) and
(ii) Damages shall be calculated less the amount of any actual tax benefits or
insurance proceeds received by Trega (discounted for any insurance premiums paid
and any delay in receipt or realization of benefits or proceeds by Trega) as a
result of any loss for which the Offset Right is asserted. Notwithstanding their
issuance and delivery into the Escrow Account, (i) the Escrow Shares shall be
and remain subject to the Offset Right for the benefit of Trega as provided in
this Section 6 and (ii) the NaviCyte Securityholders shall have no ability or
entitlement whatsoever to transfer any Escrow Shares or any interest therein
(including, without limitation, to pledge any Escrow Shares or to grant an
interest in any expectation with respect to the Escrow Shares) unless and until
such Escrow Shares are distributed to the NaviCyte Securityholders as provided
in Section 1 of this Agreement, SCHEDULE 1 hereto and the Escrow Agreement.
Without limiting the other provisions of this Agreement or the Escrow Agreement,
the NaviCyte Securityholders shall be deemed to have granted to Trega a
first-lien security interest in the Escrow Shares as collateral for the recovery
by Trega of any and all Damages pursuant to the Offset Right as provided in this
Section 6 ("TREGA'S LIEN").
(b) No Limit on Exercise. In order to exercise the Offset Right,
Trega shall not be required to (i) proceed against any person or entity
(including, without limitation, any NaviCyte Securityholder), (ii) proceed
against or exhaust any collateral or security or any part thereof or (iii)
pursue any other remedy in its power, and NaviCyte waives any defense arising by
reason of any inability of any other obligor to pay or any defense based on
bankruptcy or insolvency or other similar limitations on creditors' remedies
with respect to any other person. The foregoing notwithstanding, Trega shall
exercise reasonable efforts to minimize the amount of Damages with respect to
which the Offset Right will be exercised or NaviCyte Majority Stockholder
Indemnification (defined below) will be sought.
6.2 Claims Upon Escrow Shares.
(a) Exercise of Right. To exercise the Offset Right, Trega shall
deliver to the spokesperson for the NaviCyte Securityholders (the "SPOKESPERSON"
- -- see Section 6.4 below) a certificate signed by a Trega Officer (an "OFFICER'S
CERTIFICATE"):
(i) stating that Trega has incurred, paid, properly
accrued or otherwise suffered Damages in an aggregate stated amount with
respect to which Trega is entitled to recover pursuant to the Offset
Right; and
-39-
<PAGE> 40
(ii) specifying in reasonable detail the individual items
of Damages included in the amount so stated and the nature of the
misrepresentation, breach of warranty or claim to which such item is
related.
(b) Value of Shares. For the purposes of the Offset Right, each
share of Trega Common Stock (or right to acquire a share of Trega Common Stock)
constituting a portion of the Escrow Shares shall be valued at an amount equal
to the average closing price per share of Trega Common Stock on the Nasdaq
National Market for the twenty (20) trading days preceding the date Damages are
fixed. In the absence of a dispute regarding the amount of Damages, the date
Damages are deemed fixed for purposes of the Offset Right shall be the date of
the related Officer's Certificate.
6.3 Objections to Claims. For a period of thirty (30) days following the
time of delivery of an Officer's Certificate to the Spokesperson, no exercise of
the Offset Right for the Damages referenced in such Officer's Certificate shall
be deemed to occur unless Trega receives written authorization from the
Spokesperson. After the expiration of such thirty (30) day period, the Offset
Right shall be deemed perfected and the amount of the Escrow Shares otherwise
available for distribution (with reference to SCHEDULE 1) shall be reduced
accordingly (with the Escrow Shares at issue deemed thereupon forfeited to, and
reacquired by, Trega) unless (a) the Spokesperson shall object in a written
statement delivered to Trega to the claims made in the Officer's Certificate and
(b) such statement shall have been delivered to Trega prior to the expiration of
such thirty (30) day period.
6.4 Spokesperson. Initially, George M. Grass shall be the Spokesperson;
however, a successor to the Spokesperson may be chosen by NaviCyte
Securityholders holding at least 50% of the then present percentage interests in
the Escrow Shares.
6.5 Resolution of Conflicts. If the Spokesperson shall object in writing
to an exercise of the Offset Right by Trega in respect of any claim or claims
made in any Officer's Certificate, the Spokesperson and Trega shall attempt in
good faith to agree upon the rights of the respective parties with respect to
each of such claims within sixty (60) days after objection by the Spokesperson.
If the Spokesperson and Trega should so agree on a claim, a memorandum setting
forth such agreement shall be prepared and signed by both parties (with a
statement of the number of Escrow Shares, if any, deemed thereupon forfeited to,
and reacquired by, Trega). If the Spokesperson and Trega are unable to resolve
any claim, the matter shall be referred to Dispute Resolution (as defined below
in Section 8.9).
6.6 Spokesperson; Powers of Attorney.
(a) Attorney-in-Fact. The Spokesperson shall be deemed to be
appointed and constituted agent and attorney-in-fact by each NaviCyte
Securityholder who does not exercise dissenter's rights in respect of the
Merger, for and on behalf of such NaviCyte Securityholder, to do the following:
(i) to give and receive notices and communications; (ii) to authorize recovery
by Trega against the Escrow Shares in satisfaction of claims by Trega; (iii) to
object to such recovery; (iv) to agree to, negotiate, enter into settlements and
compromises of, and comply with orders of courts and awards of arbitrators with
respect to, claims by Trega; (v) to
-40-
<PAGE> 41
waive or settle any and all rights of NaviCyte Securityholders with respect to
the issuance or delivery of Escrow Shares; (vi) to participate in Dispute
Resolution; (vii) to resolve, with full authority to settle in any manner, any
Dispute (as defined below in Section 8.9); (viii) to take all actions necessary
or appropriate in the judgment of the Spokesperson for the accomplishment of any
of the foregoing; and (ix) to receive any Escrow Shares otherwise to be
distributed in a Tranche and to liquidate all or an appropriate portion thereof
for purposes of paying the costs associated with any of the foregoing. The
Spokesperson may resign upon thirty (30) days' notice to the Corporate Parties.
The Spokesperson may be replaced by the NaviCyte Securityholders from time to
time upon not less than five (5) days' prior written notice to Trega; provided,
however, that the Spokesperson may not be replaced unless holders of at least
50% of the then present percentage interests in the Escrow Shares agree to such
replacement. No bond shall be required of the Spokesperson, and the Spokesperson
shall receive no compensation for his or her services. Notice or communications
to or from the Spokesperson shall constitute notice to or from each of the
NaviCyte Securityholders.
(b) No Liability. The Spokesperson shall not be personally liable
for his or her service in such capacity to Trega, the Surviving Corporation or
the NaviCyte Securityholders for any act done or omitted hereunder as the
Spokesperson while acting in good faith. The NaviCyte Securityholders shall
jointly and severally indemnify the Spokesperson and hold the Spokesperson
harmless against any loss, liability or expense incurred without bad faith on
the part of the Spokesperson and arising out of or in connection with the
acceptance or administration of the Spokesperson's duties hereunder.
6.7 Actions of Spokesperson. A decision, act, consent or instruction of
the Spokesperson shall constitute a decision of all the NaviCyte
Securityholders, and shall be final binding and conclusive upon each of the
NaviCyte Securityholders, and Trega may rely upon any decision, act, consent or
instruction of the Spokesperson as being the decision, act, consent or
instruction of each and all of the NaviCyte Securityholders. Trega is hereby
relieved from any liability to any person for any acts done by it in accordance
with such decision, act, consent or instruction of the Spokesperson. Although
the Spokesperson shall not be obligated to obtain instructions from the NaviCyte
Securityholders prior to any decision, act, consent or instruction, if, and to
the extent that, the Spokesperson receives any written instructions from the
holders of at least 50% of the then present percentage interests in the Escrow
Shares, the Spokesperson shall comply with such instructions (which shall be
binding as if unanimously given by all NaviCyte Securityholders).
6.8 Indemnification by NaviCyte Majority Stockholders.
(a) From and after the Closing Date, each NaviCyte Majority
Stockholder shall jointly and severally indemnify and hold harmless Trega and
its successors and assigns ("NAVICYTE MAJORITY STOCKHOLDER INDEMNIFICATION")
from and against and in respect of any and all Damages which Trega or the
Surviving Corporation may suffer or incur (including, without limitation, as a
result of a decrease in or adverse effect upon the value of Trega's investment
or ownership interest in NaviCyte) to the extent of and by reason of the
inaccuracy or breach of any of the representations, warranties, covenants or
agreements of any NaviCyte
-41-
<PAGE> 42
Majority Stockholder contained in this Agreement or any documents, certificates
or agreements delivered pursuant hereto; provided, however, that:
(x) NaviCyte Majority Stockholder Indemnification shall
not be available if and to the extent Trega has successfully exercised
its Offset Right with respect to the subject Damages;
(y) to the extent that any inaccuracy or breach giving
rise to NaviCyte Majority Stockholder Indemnification does not result
from any fraud or willful action, misrepresentation or omission of any
NaviCyte Majority Stockholder, then the obligation represented by
NaviCyte Majority Stockholder Indemnification shall be non-recourse to
the NaviCyte Majority Stockholders except with respect to any Escrow
Shares (or other assets or securities) which are being held in the
Escrow Account at the time the respective claim is asserted (the
"SUBJECT SHARES"); and
(z) no Damages shall be recognized for purposes of the
NaviCyte Majority Stockholder Indemnification unless and until total
Damages (in the reasonable estimation of Trega) exceed $30,000.00 (at
which point all Damages shall be recognized).
(b) Within a reasonable period of time after which Trega becomes
aware of an event or circumstance for which it intends to seek NaviCyte Majority
Stockholder Indemnification, Trega shall provide notice to each affected
NaviCyte Majority Stockholder. Such notice shall include a summary of the
event(s) or circumstance(s) at issue. If a third party action is involved, the
NaviCyte Majority Stockholders acknowledge and agree that, without an obligation
to do so, Trega shall have the absolute right to control the defense thereof
with counsel reasonably acceptable to Trega.
(c) In the absence of any fraud or willful action,
misrepresentation or omission of any NaviCyte Majority Stockholder, any claim by
Trega for NaviCyte Majority Stockholder Indemnification shall be effective only
if notice thereof is sent to the affected NaviCyte Majority Stockholder(s) (to
the address(es) and by any method of delivery specified in Section 8.3 below),
on or before the date which is two years after the Effective Time.
ARTICLE 7
TERMINATION, AMENDMENT AND WAIVER
7.1 Termination. This Agreement may be terminated at any time prior to
the Effective Time, whether before or after approval by the stockholders of
NaviCyte:
(a) By mutual written consent of the Corporate Parties;
(b) By Trega or Acquisition Corporation, if (i) there has been a
material breach of this Agreement on the part of NaviCyte with respect to any of
its agreements,
-42-
<PAGE> 43
covenants, representations or warranties contained herein and such breach has
not been cured within five (5) business days after written notice thereof from
Trega or Acquisition Corporation or (ii) the Merger has not been consummated on
or before December 18, 1998 (and neither Trega nor Acquisition Corporation is in
breach of its obligations under this Agreement);
(c) By NaviCyte, if (i) there has been a material breach of this
Agreement on the part of Trega or Acquisition Corporation with respect to any of
their agreements, covenants, representations or warranties contained herein and
such breach has not been cured within five (5) business days after written
notice thereof from NaviCyte or (ii) the Merger has not been consummated on or
before December 18, 1998 (and NaviCyte is not in breach of its obligations under
this Agreement); or
(d) By any Corporate Party if: (i) there shall be a final
nonappealable order of a federal or state court in effect preventing
consummation of the Merger; (ii) there shall be any action taken, or any
statute, rule, regulation or order enacted, promulgated or issued or deemed
applicable to the Merger by any Governmental Entity which would make
consummation of the Merger illegal; or (iii) there shall be any action taken, or
any statute, rule, regulation or order enacted, promulgated or issued or deemed
applicable to the Merger by any Governmental Entity, which would (A) prohibit
Trega's or the Surviving Corporation's ownership or operation of all or a
material portion of the business of the Surviving Corporation, or compel Trega
or the Surviving Corporation to dispose of or hold separate all or a material
portion of the business or assets of the Surviving Corporation or Trega as a
result of the Merger or (B) render any Corporate Party unable to consummate the
Merger.
7.2 Effect of Termination. In the event of termination of this Agreement
as provided above, this Agreement shall forthwith become void and there shall be
no liability on the part of any Party (except for liability arising out of the
breach by a Party hereto of any of its representations, warranties, covenants or
agreements set forth in this Agreement).
7.3 Amendment/ Waiver. Except as provided in Section 6.6 above, this
Agreement may not be amended except by an instrument in writing signed on behalf
of all the Parties. At any time prior to the Effective Time, and subject to the
requirements of the DGCL if the stockholders of NaviCyte shall have already
approved the Merger, the Parties may (a) mutually extend the time for the
performance of any of the obligations or other acts of the Parties, (b) waive
any inaccuracies in the representations and warranties by another Party
contained herein or in any document delivered by such Party pursuant hereto and
(c) waive compliance by another Party with any of the agreements or conditions
contained herein. Any agreement on the part of the Parties to any such extension
or waiver shall be valid only if set forth in a writing signed on behalf of the
Party to be bound.
-43-
<PAGE> 44
ARTICLE 8
GENERAL
8.1 Payment of Expenses. Each Party shall pay its own fees and expenses
incurred incident to the preparation and carrying out of the transactions herein
contemplated (including legal and accounting expenses).
8.2 Survival. The representations and warranties of NaviCyte and the
NaviCyte Majority Stockholders shall survive for two years from and after the
Closing Date. The representations and warranties of Trega shall not survive the
Closing.
8.3 Notices. Any notice, request, instruction or other document to be
given hereunder by any Party to the other Parties shall be in writing and
delivered personally or sent by certified mail, postage prepaid, by courier
service, or by telecopy with confirmation copy sent by one of the above methods,
as follows:
if to Trega:
Trega Biosciences, Inc.
9880 Campus Point Drive
San Diego, CA 92121
Attention: President
Fax: (619) 410-6501
with a copy to:
Pillsbury Madison & Sutro LLP
101 West Broadway, Suite 1800
San Diego, CA 92101
Attention: T. Michael Hird, Esq.
Fax: (619) 236-1995
if to NaviCyte:
NaviCyte, Inc.
851 East Glendale Ave.
Sparks, NV 89431
Attention: President
Fax: (702) 353-3711
-44-
<PAGE> 45
with a copy to:
Baker & McKenzie
660 Hansen Way
Palo Alto, CA 94304
Attention: Jon M. Appleton
Fax: (650) 856-9299
or if to the initial Spokesperson (with respect to Dr. Grass) and/or any
NaviCyte Majority Stockholder:
George M. Grass, Ph.D.
c/o NaviCyte, Inc.
851 East Glendale Ave.
Sparks, NV 89431
Attention: George M. Grass, Ph.D.
Fax: (702) 353-3711
Patrick J. Sinko, Ph.D.
NaviCyte, Inc.
851 East Glendale Ave.
Sparks, NV 89431
Attention: Patrick J. Sinko, Ph.D.
Fax: (702) 353-3711
or to such other persons as may be designated in writing by the parties, by a
notice given as aforesaid.
8.4 Headings/Gender/Plural. The headings of the several sections of this
Agreement are inserted for convenience of reference only and are not intended to
affect the meaning or interpretation of this Agreement. Any reference to the
masculine, feminine or neutral gender shall be deemed to include any or all
other genders as appropriate. Any reference to the singular form of a word or
phrase shall be deemed to include or mean the plural, if appropriate, and vice
versa.
8.5 Counterparts. This Agreement may be executed in counterparts, and
when so executed each counterpart shall be deemed to be an original, and said
counterparts together shall constitute one and the same instrument.
8.6 Binding Nature. This Agreement shall be binding upon and inure to
the benefit of the parties hereto. No Party may assign or transfer any rights
under this Agreement.
8.7 Merger of Documents. This Agreement and all agreements and documents
contemplated hereby constitute one agreement and are interdependent upon each
other in all respects, and shall constitute the entire agreement between the
Parties with respect to the subject matter hereof and shall supersede all
previous negotiations, understandings, agreements,
-45-
<PAGE> 46
commitments and writings with respect to such subject matter; provided, however,
that the provisions of the following agreements between Trega and NaviCyte shall
remain in full force and effect and shall not be modified by the provisions of
this Agreement: (a) that certain Confidentiality Agreement dated as of June 22,
1998; (b) that certain Memorandum of Understanding dated as of June 22, 1998;
(c) that certain Memorandum of Understanding dated as of September 23, 1998; and
(d) that certain letter agreement dated as of the date hereof (which also
includes the NaviCyte Majority Stockholders as parties).
8.8 Incorporation. All Exhibits and Schedules attached hereto are by
this reference incorporated herein and made a part hereof for all purposes as if
fully set forth herein.
8.9 Resolution of Disputes.
(a) Negotiation of Disputes. The Parties shall attempt in good
faith to resolve any dispute arising out of or relating to this Agreement, or
the breach, termination or validity hereof (including the determination of the
interpretation or scope of the agreement to arbitrate set forth in this Section
8.9 in any event, a "DISPUTE"), by negotiations between representatives who
have authority to settle the controversy. Any Party (including, without
limitation, the Spokesperson) may give the other Parties written notice of any
Dispute not resolved in the normal course of business. Within 20 days after
delivery of such notice, representatives of all involved Parties shall meet at a
mutually acceptable time and place, and thereafter as often as they reasonably
deem necessary, to exchange relevant information and to attempt to resolve the
Dispute. If the matter has not been resolved within 60 days of the disputing
Party's notice, or if the Parties fail to meet within 20 days, any involved
Party may initiate arbitration of the controversy or claim as provided
hereinafter. If a negotiator intends to be accompanied at a meeting by an
attorney, the other negotiator(s) shall be given at least three working days'
notice of such intention and may also be accompanied by an attorney. All
negotiations pursuant to this Section 8.9 are confidential and shall be treated
as compromise and settlement negotiations for purposes of the Federal Rules of
Evidence and state rules of evidence.
(b) Arbitration. If a Dispute has not been resolved by
negotiation as provided herein, it shall be settled by binding arbitration in
accordance with the Center for Public Resources Institute for Dispute Resolution
Rules for Non-Administered Arbitration of Business Disputes. The arbitration
shall take place in San Diego, California, shall be governed by the United
States Arbitration Act, 9 U.S.C. Sections 1-16, and judgment upon the award
rendered by the arbitrator may be entered by any court having jurisdiction
thereof.
(c) Exclusive Method. The foregoing method of resolving Disputes
(herein referred to as "DISPUTE RESOLUTION") shall constitute the sole and
exclusive method, means and procedure to resolve any Dispute and THE PARTIES
HEREBY IRREVOCABLY WAIVE ANY AND ALL RIGHTS TO THE CONTRARY AND SHALL AT ALL
TIMES CONDUCT THEMSELVES IN STRICT, FULL, COMPLETE AND TIMELY ACCORDANCE WITH
THE REQUIREMENTS OF DISPUTE RESOLUTION. ANY AND ALL ATTEMPTS TO CIRCUMVENT THE
PROVISIONS OF THIS SECTION 8.9 SHALL BE ABSOLUTELY NULL AND VOID AND OF NO FORCE
OR EFFECT WHATSOEVER.
-46-
<PAGE> 47
8.10 Definitions of "Actual Knowledge" and "Best Knowledge". Where any
representation or warranty contained in this Agreement is expressly qualified by
reference to "Actual Knowledge," the Party making the representation shall be
deemed to have "Actual Knowledge" of a particular fact or other matter if the
Party actually is aware of such fact or other matter. Where any representation
or warranty contained in this Agreement is expressly qualified by reference to
"Best Knowledge," such term shall include knowledge of facts that a reasonably
prudent person would be expected to discover or otherwise become aware of in the
course of conducting a reasonably comprehensive investigation concerning the
existence of such fact or other matter.
8.11 Nasdaq References. Where reference is made in this Agreement to the
trading price of Trega Common Stock on the Nasdaq National Market, any such
reference shall be deemed modified to mean the primary trading market for Trega
Common Stock if such market is not then the Nasdaq National Market or, in the
absence of an active and organized national market for Trega Common Stock, a
determination in the good faith and reasonable discretion of the Board of
Directors of Trega regarding an appropriate price for Trega Common Stock.
8.12 No Third Party Beneficiaries. Except with respect to (i) the
delivery of Per Share Merger Consideration as and when provided in this
Agreement (i.e., pursuant to Section 1 of this Agreement, SCHEDULE 1 hereto and
the Escrow Agreement) and (ii) the provision of certain registration rights
under the circumstances contemplated by Section 4.10 of this Agreement and
SCHEDULE 5 hereto, nothing in this Agreement, express or implied, is intended to
or shall be deemed to confer upon any person or entity (including, without
limitation, any NaviCyte Securityholder) any right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement.
8.13 Severability. Should any one or more of the provisions of this
Agreement or of any agreement entered into pursuant to this Agreement be
determined to be illegal or unenforceable in any relevant jurisdiction, then
such illegal or unenforceable provision shall be modified by the proper court,
if possible, but only to the extent necessary to make such provision
enforceable, and such modified provision and all other provisions of this
Agreement and of each other agreement entered into pursuant to this Agreement
shall be given effect separately from the provision or portion thereof
determined to be illegal or unenforceable and shall not be affected thereby;
provided, however, that any such modification shall apply only with respect to
the operation of this Agreement (or any affected agreement entered into pursuant
to this Agreement) in the particular jurisdiction in which such determination of
illegality or unenforceability is made.
8.14 Adjustments and Successors. Without limiting the other provisions
hereof, this Agreement shall be binding upon and shall inure to the benefit of
any successors or assigns of Trega. The number of shares of Trega Common Stock
which may be issuable or distributed hereunder (including, without limitation,
pursuant to the Escrow Agreement) shall be appropriately adjusted to reflect any
stock dividend, stock split, combination, reclassification, recapitalization or
other similar event affecting the number of outstanding shares of Trega Common
Stock. In case of any consolidation or merger of Trega with or into any other
corporation, entity or person, or any other corporate reorganization, in which
Trega shall not
-47-
<PAGE> 48
be the continuing or surviving entity of such consolidation, merger or
reorganization, or any transaction in which in excess of fifty percent (50%) of
Trega's voting power is transferred, or any sale of all or substantially all of
the assets of Trega (any such transaction being hereinafter referred to as a
"REORGANIZATION"), then, in each case, in lieu of any shares of Trega Common
Stock issuable or available for distribution hereunder following the
effectiveness of such Reorganization, there shall be issued or distributed as
and when called for by this Agreement such stock and other securities and
property (including cash) to which a holder of such shares of Trega Common Stock
would have been entitled as part of (and at the time of) such Reorganization.
8.15 Applicable Law. This Agreement shall be governed by, construed and
enforced in accordance with, the laws of the State of California as applied to
contracts entered into solely between residents of, and to be performed entirely
in, such state.
[Remainder of this page intentionally left blank]
-48-
<PAGE> 49
IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed and attested (in the case of each of the Corporate Parties, by their
respective officers thereunto duly authorized), all as of the date first above
written.
NAVICYTE, INC., a Delaware corporation
ATTEST: By /s/ GEORGE M. GRASS
---------------------------------------
/s/ PATRICK J. SINKO Title CEO
- -------------------------- ------------------------------------
TBNC ACQUISITION CORPORATION,
a Delaware corporation
ATTEST: By /s/ DEBRA K. LIEBERT
---------------------------------------
/s/ LAWRENCE D. MUSCHECK Title CEO
- -------------------------- ------------------------------------
TREGA BIOSCIENCES, INC., a Delaware
corporation
ATTEST: By /s/ ROBERT S. WHITEHEAD
---------------------------------------
/s/ LAWRENCE D. MUSCHECK Title CEO
- -------------------------- ------------------------------------
NAVICYTE MAJORITY STOCKHOLDERS (in their individual capacities and, with respect
to Dr. Grass, as the Spokesperson):
/s/ GEORGE M. GRASS /s/ PATRICK J. SINKO
- -------------------------- -----------------------------------------
GEORGE M. GRASS, PH.D., PATRICK J. SINKO, PH.D.,
an individual an individual
-49-
<PAGE> 50
INDEX OF EXHIBITS
<TABLE>
<CAPTION>
Exhibit Description
- ------- -----------
<S> <C>
A Delaware Certificate of Merger
B NaviCyte Charter
C Escrow Agreement
D-1 Form of Investor Questionnaire
D-2 Form of Representation Letter
E-1 Employment Agreement for George M. Grass
E-2 Employment Agreement for Patrick J. Sinko
F Form of Legal Opinion for Counsel to NaviCyte
G Form of Legal Opinion for Counsel to Trega
</TABLE>
* The exhibits and schedules have been omitted from this Agreement as filed
with the Securities and Exchange Commission (the "SEC"). The omitted
information is considered immaterial from an investor's perspective. Trega
will furnish supplementally a copy of any of the documents to the SEC upon
request of the SEC.
-50-
<PAGE> 51
INDEX OF SCHEDULES
<TABLE>
<CAPTION>
Schedule Description
- -------- -----------
<S> <C>
0 Sample Per Share Merger Consideration Calculations
1 Schedule for Distribution of Escrow Shares
2 Provisions for Substituted Options
Plus: Exhibit 2-A (the NaviCyte 1997 Stock Plan) thereto
2.2 NaviCyte Securities/Securityholders
2.5 Leases Requiring Consent
2.6 NaviCyte Financial Statements
2.7 Business Changes
2.8 Hazardous Substances
2.9 Personal Property
2.11 Employment/Compensation Schedule
2.16 Contracts
2.18(a) NaviCyte Proprietary Rights
2.18(b) NaviCyte Financial Projections
2.18(c) Proprietary Rights Exceptions
2.18(d) Unauthorized Use
2.18(e) Proceedings
2.18(j) Patent Applications
2.19 Insurance
2.20 Bank Accounts
2.25 Employee Benefits Plans
2.29 NaviCyte Affiliates
2.30 Discussions
3 NaviCyte Disclosure Schedule
4 Trega Disclosure Schedule
4.11 Guaranties by Dr. Grass
5 Registration Rights
5.2(n) Open Obligations Owed to Dr. Grass
</TABLE>
* The exhibits and schedules have been omitted from this Agreement as filed
with the Securities and Exchange Commission (the "SEC"). The omitted
information is considered immaterial from an investor's perspective. Trega
will furnish supplementally a copy of any of the documents to the SEC upon
request of the SEC.
-51-
<PAGE> 1
EXHIBIT 99.2
NAVICYTE
851 East Glendale Ave.
Sparks, NV 89431
October 11, 1998
George Grass, Ph.D.
P.O. Box 1242
Tahoe City, CA 96145
Dear George:
This letter sets forth the basic terms and conditions of your employment
with NaviCyte, Inc. ("NaviCyte"). This Agreement shall be effective upon the
acquisition of the issued and outstanding capital stock of NaviCyte by Trega
Biosciences, Inc. ("Trega") (the "Effective Date"). By signing this letter, you
will be agreeing to these terms. In addition, you agree that as of the Effective
Date, this letter will supersede the terms of any current employment agreement
between yourself and NaviCyte and any related companies (except insofar as
confidentiality, proprietary information and assignment of intellectual property
rights are concerned). It is important that you understand clearly both what
your benefits are and what is expected of you by NaviCyte.
1. Salary. You will be paid an annual base salary of $200,000 ("Base
Salary"), less regular payroll deductions (payable semi-monthly), which
compensates you for all hours worked.
2. Eligibility for Bonus. You will be eligible to earn an annual bonus
compensation award of up to sixty percent (60%) of your annual Base Salary
contingent upon an assessment by the Compensation Committee of the Trega Board
of Directors (the "Compensation Committee"), or the Trega Chief Executive
Officer (the "CEO") of your annual performance, achievement of business
objectives, achievement of pre-agreed targets in Trega common stock price
performance and other factors that are jointly agreed upon by you and the CEO,
subject to the approval of the Compensation Committee. These criteria may be
changed from time to time by agreement of yourself and the CEO, subject to the
approval of the Compensation Committee. To be eligible for a bonus, you must be
on the NaviCyte payroll when the bonus is paid. No pro-rata payment will be made
if you are not employed by NaviCyte when the bonus is paid; provided, however,
in the event you are terminated without Cause (as hereinafter defined) during
any year in which you shall have actually achieved goals prior to termination
which would have entitled you to the payment of a bonus had you remained an
employee at the time the bonus was paid, NaviCyte shall nevertheless pay you the
portion of the bonus you actually earned at the time bonuses are generally paid.
Even under such circumstances, however, you shall not be entitled to the payment
of a bonus for the partial accomplishment of any goal.
3. Incentive Stock Options. As soon as practicable following the
Effective Date, and subject to the approval of the Compensation Committee of the
Trega Board of Directors,
-1-
<PAGE> 2
you will receive a Stock Option Grant of 150,000 shares of Trega common stock
issued pursuant and subject to the Trega 1996 Stock Incentive Plan (the "Plan"),
a copy of which is attached hereto as Attachment A. The above-referenced options
shall vest either according to the Plan or pursuant to resolution of the
Compensation Committee and shall become fully vested in the event of a "Change
in Control" as defined in the Plan. You may be eligible for additional stock
option grants at the sole discretion of the Trega Board of Directors and the
Compensation Committee.
4. Duties. Your job title will be President, NaviCyte. Your duties
generally will include responsibility for all activities relating to all
business and scientific activities for NaviCyte as a wholly owned subsidiary of
Trega including corporate collaborations and negotiations and integration of
elements of the technical platform into Trega's technological base. You will
work closely with the CEO and the Trega management team in the development and
implementation of the strategic and technical planning necessary to enhance the
valuation and global recognition of NaviCyte. You may be assigned other duties
as needed and your duties may change from time to time on reasonable notice,
based on the needs of NaviCyte and Trega and your skills, as determined by the
CEO provided, however, that you will not be assigned to duties inconsistent with
your position as an executive officer or which reflect a material change in your
authority and responsibility with NaviCyte or its affiliates.
As an exempt employee, you are required to exercise your specialized
expertise, independent judgment and discretion to provide high-quality services.
You are required to follow office policies and procedures adopted from time to
time by NaviCyte and Trega and to take such general direction as you may be
given from time to time by the CEO. Trega and NaviCyte reserve the right to
change these policies and procedures at any time. (Also see Adjustments and
Changes in Employment Status.) You are required to devote your full energies,
efforts and abilities to your employment, unless NaviCyte expressly agrees
otherwise.
5. Competitive Activity. You acknowledge and agree that, as of the
Effective Date, the issued and outstanding capital stock of NaviCyte is being
acquired by Trega (the "Merger") and, as part of the Merger, you are disposing
of a significant equity interest in NaviCyte in exchange for cash and shares of
the common stock of Trega. In conjunction with the Merger (e.g., to protect the
investment which Trega is making in NaviCyte (including, without limitation, the
goodwill with respect to the business of NaviCyte) and as part of this
agreement, you agree that, at all times while you are an employee, director, or
consultant of Trega, NaviCyte, or their affiliates and for a period which shall
terminate on the earlier of: (i) the third anniversary of the Effective Date
(ii) the second anniversary of the Effective Date in the event you have
previously terminated this Agreement for "Good Reason" (as defined in paragraph
12(d) below) or (iii) the date of your termination by NaviCyte without Cause (as
defined in paragraph 12(a) below), you shall not:
(a) carry on directly or indirectly, whether or not for
compensation (as proprietor, partner, stockholder (except that a less
than one percent (1%) ownership in a public corporation shall be
permitted), officer, director, agent, employee, consultant,
-2-
<PAGE> 3
trustee, affiliate or otherwise), any business which in the reasonable
judgment of the Board of Directors of Trega or NaviCyte is, or as a
result of your engagement or participation would become, competitive
with, or adverse to any aspect of the pharmacokinetic or toxicology
characterization activities conducted by NaviCyte or Trega
(collectively, "the Business");
(b) permit your name to be used by or participate in a venture
carrying on any business competitive in any respect with the business of
the Business;
(c) solicit or divert, or attempt to call on, solicit or divert,
any customer, partner, collaborator or associate of the Business with
whom you became acquainted during your employment or affiliation with
NaviCyte or Trega, either for your benefit or for the benefit of any
other person, firm or corporation;
(d) induce or attempt to induce any person who is an employee,
agent or consultant of the Business to leave the employ of the Business;
(e) Take any other action materially inimical to the interests of
the Business.
6. Adjustments and Changes in Employment Status. You understand that
NaviCyte reserves the right to make personnel decisions regarding your
employment, including but not limited to decisions regarding any promotion,
salary adjustment, transfer or disciplinary action, up to and including
termination (in accordance with paragraph 12 below), consistent with the needs
of the business subject to the terms hereof.
7. Hours of Work. As an exempt employee, you are expected to work the
number of hours required to get the job done. However, you are generally
expected to be present during normal working hours of NaviCyte. Normal working
hours will be established by NaviCyte and may be changed as needed to meet the
needs of the business.
8. Proprietary Information Agreement. You will be required to sign and
abide by the terms of the enclosed proprietary information agreement, which is
incorporated into this Agreement by reference as Attachment B, and you may be
required to execute further agreements to protect NaviCyte's and Trega's trade
secrets and their rights to intellectual property. You also hereby reconfirm all
prior agreements of a similar nature between you and NaviCyte.
9. Representation and Warranty of Employee. You represent and warrant to
NaviCyte and Trega that, to your knowledge, the performance of your duties will
not violate any agreements with or trade secrets of any other person or entity.
10. Employee Benefits. You will be eligible for three weeks paid
vacation each calendar year. Vacation will accrue on a pro-rata basis
semi-monthly. You will receive an additional vacation day for each year of
service subject to Trega's vacation policy which places a cap on the number of
vacation days that an employee may accumulate. You will
-3-
<PAGE> 4
also be paid for sick leave and holidays also subject to Trega's policies. You
will be provided with health insurance benefits and dental insurance benefits,
as provided in our benefit plans. You will be eligible to participate in Trega's
401(k) retirement savings plan and Trega's flexible spending account. These
benefits may change from time to time. You will be covered by workers'
compensation insurance and State Disability Insurance, as required by state law.
You will be reimbursed for reasonable business expenses, which are submitted in
a timely fashion, pursuant to Trega's expense reimbursement policy.
11. Additional Benefits. You will be provided with the following
additional benefits: You will be reimbursed for reasonable relocation expenses
for (i) the move of your household goods from Tahoe City, California to San
Diego; (ii) a pre-move house hunting trip; (iii) temporary living quarters and
temporary transportation for up to thirty (30) days; and (iv) specific costs
relating to the sale and purchase of your primary residence as pre-approved by
NaviCyte. Any payments made to you or third parties on your behalf for
relocation, other than the moving of household goods and travel, are required to
be included in your gross earnings for the year. NaviCyte agrees to pay you a
cash bonus "grossed up" to compensate you for the taxes you will be required to
pay on this additional income.
12. Termination and Severance Benefits.
(a) NaviCyte and you each retain the right to terminate this Agreement
with or without Cause at any time. In the event of a termination without Cause,
you shall be entitled to the following severance benefits:
(i) Continuation of your then current rate of Base Salary in
paragraph 1 for a period not to exceed two years from the Effective
Date. For example, if you were terminated without Cause 20 months after
the Effective Date, you would be entitled to an additional four months
of salary continuation. The severance pay will be paid in semi-monthly
installments, unless the parties mutually agree otherwise;
(ii) Immediate vesting of the option referred to in paragraph 3
(which, except to the extent already vested, shall thereupon become a
non-qualifying stock option) for a period not to exceed the longer of
thirty (30) days from the date of termination or two years from the
Effective Date; and,
(iii) If you elect continuation of your health insurance under a
law known as COBRA, NaviCyte shall make the premium payments for you for
a period of 12 months from your date of termination, unless you qualify
for other comparable coverage prior to the end of the 12 months.
You shall not be entitled to any other unvested benefits of employment,
except to the extent expressly set forth herein.
(b) In the event of termination of this Agreement for Cause, you shall
not be entitled to severance or any other unvested benefits. Cause for the
purposes of this Agreement shall mean (i) your failure to achieve minimum goals
(as distinguished from bonus
-4-
<PAGE> 5
criteria) agreed upon by the CEO or the Board of Directors of Trega and you;
(ii) your failure to perform your job or neglect of your responsibilities for 30
days following notice of such failure or neglect setting forth with reasonable
particularity the items of failure or neglect; (iii) your violation of NaviCyte
or Trega policy set forth in NaviCyte's or Trega's employee policy manuals from
time to time; (iv) insubordination; (v) your failure to devote your full working
time and energy to your obligations under this Agreement; (vi) your negligence
in failing to protect NaviCyte's or Trega's trade secrets; (vii) your conviction
of a felony or misdemeanor or your engaging in acts of moral turpitude; (viii)
your engaging in other conduct injurious to NaviCyte or Trega.
(c) Voluntary Termination, Death or Disability. In the event you
terminate your employment with NaviCyte without "Good Reason" as defined below
of your own volition or as a result of death or disability, such termination
will have the same consequences as a termination for Cause under subparagraph
(b) above. A resignation requested by the Board of Directors of Trega or
NaviCyte shall in no way be deemed a voluntary termination.
(d) Termination for "Good Reason". You may terminate this Agreement for
"Good Reason" by providing NaviCyte written notice of termination of this
Agreement with a copy delivered at the same time to Trega. You agree that your
right to terminate the Agreement for Good Reason will be deemed to be waived by
your failure to provide the notice required under this paragraph within thirty
(30) days of the event constituting Good Reason. For purposes of this Agreement,
Good Reason means:
(i) at a time when your job performance is satisfactory as
reflected in your performance appraisals, a reduction in your annual
base salary below the amount reflected in paragraph 1 above or a
material adverse change in your benefits, unless such reduction or
change is part of an action to reduce the salaries or change the
benefits of NaviCyte or Trega executives generally and such reduction or
change applied to you is consistent with other reductions or changes in
such action;
(ii) the failure of any successor to NaviCyte or a purchaser of
all or substantially all of NaviCyte's assets to perform this Agreement;
(iii) your assignment to duties inconsistent with your position
as an executive officer of NaviCyte or which reflect a material change
in your authority and responsibility with NaviCyte, its affiliates or
any successor at a time when your job performance is satisfactory as
reflected in your performance appraisals.
(e) Release of Claims. As a condition to the receipt of the payments
described in subparagraph (a) above, you shall be required to execute a release
of all claims arising out of or related to your employment or the termination
thereof, including, but not limited to, any claim of discrimination under state
or federal law, but excluding claims for indemnification from NaviCyte or Trega
under any indemnification agreement, certificates of incorporation or by-laws of
NaviCyte or Trega or applicable law, or claims for directors and officers'
insurance coverage, if any.
-5-
<PAGE> 6
13. Dispute Resolution Procedure. You and NaviCyte ("the parties ")
agree that any dispute arising out of or related to the employment relationship
between them, including the termination of that relationship and any allegations
of unfair or discriminatory treatment arising under state or federal law or
otherwise, shall be resolved by final and binding arbitration, except where the
law specifically forbids the use of arbitration as a final and binding remedy,
or where paragraph (g) below specifically allows a different remedy. The
following dispute resolution procedure shall apply:
(a) The party claiming to be aggrieved shall furnish to the other party
a written statement of the grievance identifying any witnesses or documents that
support the grievance and the relief requested or proposed.
(b) The responding party shall furnish a statement of the relief, if
any, that it is willing to provide, and the witnesses or documents that support
its position as to the appropriate action. The parties can mutually agree to
waive this step. If the matter is not resolved at this step, the parties shall
submit the dispute to nonbinding mediation before a mediator to be jointly
selected by the parties. NaviCyte will pay the cost of the mediation.
(c) If the mediation does not produce a resolution of the dispute, the
parties agree that the dispute shall be resolved by final and binding
arbitration. The parties shall attempt to agree to the identity of an
arbitrator, and, if they are unable to do so, they will obtain a list of
arbitrators from the Federal Mediation and Conciliation Service and select an
arbitrator by striking names from that list.
(d) The arbitrator shall have the authority to determine whether the
conduct complained of subparagraph (a) of this paragraph violates the rights of
the complaining party and, if so, to grant any relief authorized by law, subject
to the exclusions of paragraph (g) below. The arbitrator shall not have the
authority to modify, change or refuse to enforce the terms of any employment
agreement between the parties. In addition, the arbitrator shall not have the
authority to require NaviCyte or Trega to change any lawful policy or benefit
plan.
(e) The hearing shall be transcribed. NaviCyte shall bear the costs of
the arbitration if you prevail. If NaviCyte prevails, you will pay half the cost
of the arbitration or $500, whichever is less. The prevailing party in any such
arbitration shall be entitled to recover its actual reasonable attorneys' fees
in connection with the arbitration and the enforcement of the arbitrator's
award.
(f) ARBITRATION SHALL BE THE EXCLUSIVE FINAL REMEDY FOR ANY DISPUTE
BETWEEN THE PARTIES, INCLUDING BUT NOT LIMITED TO DISPUTES INVOLVING CLAIMS FOR
DISCRIMINATION OR HARASSMENT (SUCH AS CLAIMS UNDER THE FAIR EMPLOYMENT AND
HOUSING ACT, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE AMERICANS WITH
DISABILITIES ACT, OR THE AGE DISCRIMINATION IN EMPLOYMENT ACT), WRONGFUL
TERMINATION, BREACH OF CONTRACT, BREACH OF PUBLIC POLICY, PHYSICAL OR MENTAL
HARM OR DISTRESS OR ANY OTHER DISPUTES, AND THE PARTIES AGREE THAT NO DISPUTE
SHALL BE SUBMITTED TO ARBITRATION WHERE THE PARTY CLAIMING TO BE AGGRIEVED HAS
NOT COMPLIED WITH THE PRELIMINARY STEPS PROVIDED FOR IN SUBPARAGRAPHS (a)
-6-
<PAGE> 7
AND (b) ABOVE, EXCEPT THAT DISPUTES WITH AN AMOUNT OF LESS THAN $25,000 NEED NOT
BE SUBMITTED TO MEDIATION.
(g) The parties agree that the arbitration award shall be enforceable in
any court having jurisdiction to enforce this Agreement, so long as the
arbitrator's findings of fact are supported by substantial evidence on the whole
and the arbitrator has not made errors of law; provided however, that either
party may bring an action, including but not limited to an action for injunctive
relief, in a court of competent jurisdiction regarding or related to matters
involving NaviCyte's or Trega's confidential, proprietary or trade secret
information, or regarding or related to inventions that you may claim to have
developed prior to joining NaviCyte or after joining NaviCyte, pursuant to
California Labor Code section 2870 ("Disputes Related to Inventions"). The
parties further agree that for Disputes Related to Inventions which the parties
have elected to submit to arbitration, each party retains the right to seek
preliminary injunctive relief in court in order to preserve the status quo or
prevent irreparable injury before the matter can be heard in arbitration.
14. Integrated Agreement. Please note that this Agreement supersedes any
prior agreements, representations or promises of any kind, whether written,
oral, express or implied between the parties hereto with respect to the subject
matters herein. It constitutes the full, complete and exclusive agreement
between you and NaviCyte with respect to the subject matters herein. This
Agreement cannot be changed unless in writing, signed by you and the then
current Chairman of the Board of NaviCyte.
15. NaviCyte is a Third Party. Since NaviCyte will be a wholly-owned
subsidiary of Trega from the Effective Date, it is intended that Trega shall be
a third-party beneficiary for purposes of this Agreement.
16. Severability. If any term of this Agreement is held to be invalid,
void or unenforceable, the remainder of this Agreement shall remain in full
force and effect and shall in no way be affected; and, the parties shall use
their best efforts to find an alternative way to achieve the same result.
In order to confirm your agreement with and acceptance of these terms,
please sign one copy of this letter and return it to me. The other copy is for
your records. If there is any matter in this letter which you wish to discuss
further, please do not hesitate to speak to me.
Very Truly yours,
NaviCyte, Inc.
By: /s/ GEORGE M. GRASS
------------------------------------------
George M. Grass, Ph.D.
Title: President
----------------------------------------
-7-
<PAGE> 8
I agree to the terms of employment set forth in this Agreement.
/s/ George M. Grass 11/10/98
- -------------------------------- ------------------
George M. Grass, Ph.D. Date
* The exhibits and schedules have been omitted from this Agreement as filed
with the Securities and Exchange Commission (the "SEC"). The omitted
information is considered immaterial from an investor's perspective. Trega
will furnish supplementally a copy of any of the documents to the SEC upon
request of the SEC.
-8-
